

# Index to Volume 36

The index to Volume 36 is composed of three parts: a subject index, an author index and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended controlled vocabulary index which makes use of standardized headings. (The primary index terms for each article are listed routinely in the *Journal* as "key words" following article abstracts.) The subject index also notes all regular *Journal* columns and, under the respective column headings, the titles of editorials and books reviewed, the items covered in "Equipment and Supplies," the titles of individual stories in "News" items, and reports from affiliated chapters in "ASHP Affiliates." Under "News," items covered in "Appointments and Promotions" and in "News Briefs" are listed after those subheadings. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page number on which the correction appeared.

<i>Issue</i>	<i>Pages</i>	<i>Issue</i>	<i>Pages</i>
January	1-130	July	863-1000
February	131-270	August	1001-1134
March	271-418	September	1135-1284
April	419-570	October	1285-1446
May	571-714	November	1447-1614
June	715-862	December	1615-1750

## Subject Index

### A

#### **Absorption**

aminophylline; oral, effects, aluminum hydroxide, combination, magnesium hydroxide, patients, 1059  
aspirin; effects, charcoal activated, comparison, kaolin, combination, pectin, patients, 1097  
dipyridine; patients, 1179

#### **Acetaminophen**

combination, oxycodone; therapy, symptoms, folic acid allergies, patient, 1565  
hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674  
information; comparison, services, 1215

#### **Additives**

incompatibilities; glycopyrrolate, effects, pH, 508  
injections; cefazolin sodium, effects, membrane filters, on concentration and particle contamination, in sodium chloride and dextrose in water, 657; cefoxitin sodium, stability, 33; diazepam, i.v., incompatibilities, plastics, 506; equipment, comparison, systems, contamination, costs and workload, 1497; FreAmine II, incompatibilities, 511; heparin sodium, stability, pH and time, in dextrose in water and dextrose in sodium chloride, 618; insulin, low-dose continuous, effects, availability, 330; intravenous, osmolarity, methods, 1357; stability, glycopyrrolate, 508

#### **Administration**

clinical pharmacy; services, strategy, increased demand, hospitals, 1553  
hospital pharmacy; amino acids, parenteral nutrition solutions, concentration, formulary change, 57  
personnel, pharmacy; evaluations, methods, 187  
pharmacists, hospital; performance, appraisal, method, 1676  
policies and procedures; manuals, admixture services, parenteral nutrition, development, review, 517

**Admixture services;** injections, hospitals, survey, 1978; comparison, 1975, 316; policies and procedures, manuals, review, 517

**Admixtures;** injections; containers, plastics, dextrose in water, compounding times and contamination rates, 513; contamination during sterility testing, 1493; control, quality, methods and programs, 605

#### **Adsortion**

insulin; injections, low-dose, continuous, effects, and solution type, container, administration set, concentration and rate, 330  
nitroglycerin; containers, plastics, extemporaneous i.v. injections, 173

sodium salicylate; charcoal, activated, reduced by sucrose, in vitro, 797

sucrose; charcoal, activated, lack, in vitro, 797

**Adulteration;** meperidine hydrochloride; dosage forms, visual, colorimetry and UV spectrometry, 1094

**Advertising Index,** 128, 264, 418, 570, 714, 862, 1000, 1134, 1284, 1446, 1614, 1734

**AJHP Continuing Education,** 11, 139, 279, 427, 581, 721, 869, 1011, 1145, 1291, 1453, 1623

#### **Albumin**

cardioplegic solutions; stability, effects, 1361  
drug use review; prescribing, hospitals, 1205

#### **Allergies**

allopurinol; patients, 1377

folic acid; patient, 1565

#### **Allopurinol**

allergies; patients, 1377

gout; and hyperuricemia, therapy, discussion, 497  
sarcoïdosis; therapy, discussion, 351

#### **Aluminum hydroxide**

combination, magnesium hydroxide; absorption, oral aminophylline, effects, patients, 1059

combination, magnesium hydroxide, simethicone; tablets, equivalence, generic, acid reactivity, in vitro, 666

**Ambulatory care;** patients; pharmacists, role, clinic, screening and prescribing, 916

#### **American Journal of Hospital Pharmacy**

acknowledgment to reviewers, 1661  
notice to authors, 850, 1485  
statement of ownership, management and circulation, 1552

#### **American Society of Hospital Pharmacists**

accreditation standard for pharmacy residency in a hospital, 74

affiliated state chapter officers, 962

Board of Directors; actions, November 16-17, 1978 meeting, 224; March 22-23, 1979 meeting, 965; April 21, 1979 meeting, 966; July 30-31, 1979 meeting, 1559

councils call for agenda suggestions, 964

Council on Clinical Pharmacy and Therapeutics; report of, 949

Council on Education and Manpower; report of, 950

Council on Legal and Public Affairs; report of, 952

Council on Organizational Affairs; report of, 954

Council on Professional Affairs; report of, 956

Donald E. Francke Medal lecture, 492

education; topics, 1967-1978, Midyear Clinical Meeting papers, 1372

Executive Vice President; report of, 944

Guidelines for obtaining authorization for pharmacists' notations in the patient medical record, 222

Guidelines for repackaging oral solids and liquids in single unit and unit dose packages, 223

Guidelines for the use of investigational drugs in institutions, 221

Harvey A. K. Whitney Lecture Award; 1978, 311

House of Delegates, 30th annual session; members of, 936; proceedings of, 934

Midyear Clinical Meeting, 1979; program, 1391

officers, directors, councils and committees; directory of, 957

President and Chairman of the Board; report of, 938

President-elect and Vice Chairman of the Board; report of, 941

Residents in training in accredited programs; calendar year 1978, 663

Statement of accreditation of pharmacy residencies in hospitals, 72

Treasurer; report of, 946

**American Society of Hospital Pharmacists Residency Matching Program;** residences; hospitals, screening and selection procedure, 194

#### **Amikacin**

and ticarcillin; toxicity, ear, leukopenic patients, 1083

drug use review; pharmacists, hospital, 1209

**Amikacin sulfate;** incompatibilities; cefoxitin sodium, lack, in vitro, 33

#### **Amino acids**

adverse reactions; rash, due to fatty acid deficiency, patient, 230

concentration; parenteral nutrition, solutions, formulary change, hospitals, 57

#### **Aminoglycosides**

antibiotic; costs, pharmacists, hospital, role, 1209; toxicity, ear, leukopenic patients, 1083

blood levels; rational therapy, pharmacists, role, 1080  
dosage schedules; computers, costs, hospitals, 368  
infections; combined therapy, granulocytic cancer patients, 178

#### **Aminophylline**

absorption; oral, lack, effects, aluminum hydroxide, combination, magnesium hydroxide, patients, 1059  
dosage; oral, determination, using clearance rates following i.v. infusion, patients, 66

tablets; comparison, theophylline sustained-action tablets, effects and blood levels, patients, 613

#### **Amoxicillin trihydrate**

stability; temperature, freezing, effects, reconstituted unit dose, 209

#### **Amphotericin B**

incompatibilities; FreAmine II, visual, 511  
mechanism of action; toxicity, dosage, availability and costs, review, 1326

#### **Ampicillin**

hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674

stability; temperature, freezing, effects, reconstituted unit dose, 209

toxicity; diarrhea, prophylaxis, *Lactobacillus acidophilus*, combination, *Lactobacillus bulgaricus*, patients, 754; skin, patients, 609

**Ampicillin sodium;** incompatibilities; FreAmine II, visual, 511

**Amplus;** stannous chloride dihydrate; ions stannous, effects, stability, radiopharmaceutical kits, 1370

#### **Analgesics and antipyretics**

butorphanol tartrate; therapy, review, 1683

costs; hospitals, and drug use, 1347

injections; self-medication, costs, effects, clinical pharmacists training programs, inpatient, 1527

meperidine hydrochloride; dosage forms, adulteration, visual, colorimetry and UV spectrometry, 1094

phenothiazines; rational therapy, review, 633

therapy; review, 622

**Analysis;** microbiological; penicillin V potassium, stability, oral plastic syringes, various temperatures, 205

**Anemia;** Cooley's; deferoxamine, self-medication, patient, pharmacist, hospital, role, 788

#### **Antacids**

aluminum hydroxide, combination, magnesium hydroxide; lack, effects, oral aminophylline absorption, patients, 1059

aluminum hydroxide, combination, magnesium hydroxide, simethicone; tablets, equivalence, generic, and reactivity, in vitro, 666

interactions; tetracycline, monitoring, programs, outpatients, 653

#### **Antidiabetics**

aminoglycosides; costs, pharmacists, hospital, role, 1209

drug use review; amikacin, and tobramycin, hospital pharmacists, 1209; cefazolin, prescribing, control, programs, hospital, 1055; hospitals, systems, problems, 376

incompatibilities; FreAmine II, 511

prescribing; effects, length of hospital stay, pylonephritis patients, 1334

#### **Anticoagulants**

coumarin derivatives; drug interactions, monitoring, Medicaid patients, 923

heparin; dosage schedules, effects, costs, tests and errors, 220; injections, rates, methodology, comparison, patient weight and pharmacokinetic model, 782; solutions, use, cytopathology, bottles, collection of body cavity fluids,

- 211; thrombopenia, patients, 1561  
heparin sodium and warfarin sodium; drug use review, pharmacists, hospital, embolism, thrombosis and thrombophlebitis, 214  
pharmacists, hospital; role, clinic, ambulatory, development, operation, patient management protocols and education, 645  
warfarin sodium; dosage, methodology, prothrombin time, patients, 1351  
warfarin sodium and heparin sodium; drug use review, pharmacists, hospital, embolism, thrombosis and thrombophlebitis, 214
- Anticoagulants;** phenytoin; information, comparison, services, 1215
- Antidiabetic agents**  
patients; clinical pharmacists, role, management, 1321  
tolbutamide; hyponatremia, patients, 1107; tablets, stability, storage, counting machine, spectrometry and colorimetry 1539
- Antidiarrheal agents**  
*Lactobacillus acidophilus*, combination, *Lactobacillus bulgaricus*; prophylaxis, ampicillin-induced diarrhea, patients, 754  
*Lactobacillus bulgaricus*, combination, *Lactobacillus acidophilus*; prophylaxis, ampicillin-induced diarrhea, patients, 754  
therapy; review, 757
- Antidotes**  
atropine sulfate; injections, therapy, clonidine overdose, review, 906  
charcoal activated; comparison, kaolin, combination, pectin, effects, aspirin absorption, patients, 1097  
therapy, clonidine overdose, review, 906  
cholestyramine resin; poisoning, digitoxin, patients, 92  
colestipol hydrochloride; poisoning, digitoxin, patients, 92  
dopamine; injections, therapy, clonidine overdose, review, 906  
kaolin, combination, pectin; comparison, charcoal activated, effects, aspirin absorption, patients, 1097  
lidocaine hydrochloride; poisoning, digitoxin, patients, 92  
pectin, combination, kaolin; comparison, charcoal activated, effects, aspirin absorption, patients, 1097  
potassium chloride; poisoning, digitoxin, patients, 92  
tolazoline; rational therapy, clonidine overdose, review, 906
- Antihemophilic factor human;** self-medication; costs, effects, clinical pharmacists training programs, inpatients, 1527
- Antihistamines;** chlorpheniramine maleate; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539
- Anti-infective agents;** prescribing; effects, length of hospital stay, pyelonephritis patients, 1334
- Anti-inflammatory agents;** therapy; review, 622
- Antineoplastic agents**  
cytarabine; self-medication, costs, effects, clinical pharmacists training programs, inpatients, 1527  
doxorubicin hydrochloride; injections, stability, temperature, effects, 1536
- Antiparkinson agents;** extrapyramidal disorders; prophylaxis, psychotherapeutic agent-induced, patients, 641
- Antirheumatic agents;** therapy; review, 622
- Arthritis;** therapy; review, 622
- Ascorbic acid;** tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539
- ASHP,** see American Society of Hospital Pharmacists
- ASHP Affiliates,** 17, 146, 284, 431, 587, 728, 872, 1016, 1148, 1297, 1458, 1630  
Alabama Society of Hospital Pharmacists, 146, 284, 587, 1148, 1297  
Arizona State Council of Hospital Pharmacists, 146, 1630  
California Society of Hospital Pharmacists, 17, 146, 284, 431, 872, 1148  
Colorado Society of Hospital Pharmacists, 1297  
Connecticut Society of Hospital Pharmacists, 431, 587, 728, 1630  
District of Columbia Society of Hospital Pharmacists, 1297  
Florida Society of Hospital Pharmacists, 17, 284, 1016  
Georgia Society of Hospital Pharmacists, 18, 587, 872, 1639  
Idaho Society of Hospital Pharmacists, 18, 872  
Indiana Society of Hospital Pharmacists, 1016  
Iowa Society of Hospital Pharmacists, 431, 1458  
Kansas Society of Hospital Pharmacists, 1297, 1639  
Louisiana Society of Hospital Pharmacists, 1016, 1639  
Maine Society of Hospital Pharmacists, 18, 431, 1646  
Maryland Society of Hospital Pharmacists, 18, 284, 431, 728, 1021, 1148, 1646  
Massachusetts Society of Hospital Pharmacists, 18, 286, 1021
- Michigan Council of Hospital Pharmacists, 431  
Minnesota Society of Hospital Pharmacists, 19, 590, 729  
Missouri Society of Hospital Pharmacists, 19, 875, 1646  
Montana Society of Hospital Pharmacists, 1458  
Nebraska Society of Hospital Pharmacists, 19, 431, 875  
New Jersey Society of Hospital Pharmacists, 146, 729, 878, 1297  
New York State Council of Hospital Pharmacists, 19, 286, 878  
North Carolina Society of Hospital Pharmacists, 432  
Ohio Society of Hospital Pharmacists, 146  
Oregon Society of Hospital Pharmacists, 432, 729, 1021  
Pennsylvania Society of Hospital Pharmacists, 729, 1021, 1650  
Rhode Island Society of Hospital Pharmacists, 732, 1150  
Texas Society of Hospital Pharmacists, 732, 1458  
Vermont Society of Hospital Pharmacists, 1297  
Virginia Society of Hospital Pharmacists, 590, 1022, 1650  
West Virginia Society of Hospital Pharmacists, 878  
Wisconsin Society of Hospital Pharmacists, 878, 1458
- Aspirin**  
absorption; effects, charcoal activated, comparison, kaolin, combination, pectin, patients, 1097  
hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674  
interactions; phenothiazines, potentiation, review, 633  
tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539
- Asthma;** theophylline; tablets, sustained-action, dosage schedules, blood levels, children, 1698
- Atropine;** diarrhea; therapy, discussion, 757
- Atropine sulfate;** therapy; clonidine, overdose, review, 906
- Audiovisual aids;** patients; education, theophylline, with and without pharmacists present, 63
- Automation, data processing, computers**  
adverse reactions; monitoring, programs, hospitalized patients, 198  
aminoglycosides; dosage schedules, costs, 368  
dosage schedules; pharmacokinetics, clinical pharmacists, development and reimbursement, 1523  
drug use review; hypotensive agents, comparison, methods, family practice clinic, 1665  
hospital pharmacy; comparison, word-processing machines, 1529; files, multi-functional drug, development, 1197; outpatients, services, 1978 survey, university-affiliated hospitals, 1193  
pharmaceutical services; drugs, pricing, hospitals using a markup and a dose fee, 360
- Azathioprine;** polychondritis, relapsing; therapy, patient, 806
- B**
- Benzoic acid;** preservatives; effects, adulteration tests on meperidine hydrochloride, 1094
- Blood levels**  
aminoglycosides; dosage schedules, computers, costs, 368; rational therapy, pharmacists, role, 1080  
aminophylline; lack, effects, aluminum hydroxide, combination, magnesium hydroxide, patients, 1059; tablets, comparison, sustained-action theophylline tablets, patients, 613  
digoxin; increased, quinidine, patient, 968  
dypheylline; patients, 1179  
gentamicin; acsitic patients, 1704  
lidocaine hydrochloride; withdrawal, myocardial infarction patients, 778  
naproxen; hemodialysis, effects, patients, 1567  
spironolactone; effects, neomycin sulfate, patients, 1701  
theophylline; dosage, oral, using clearance rates following i.v. aminophylline infusion, patients, 66; tablets, sustained-action, comparison, regular aminophylline tablets, patients, 613; tablets, sustained-action, dosage schedules, asthmatic children, 1698
- Books Reviews,** 109, 386, 531, 698, 823, 976, 1114, 1247, 1416, 1579, 1719  
*Annual Review of Pharmacology and Toxicology, Volume 19,* 1247  
*APhA Drug Names, Second Edition,* 823  
*Arterial Hypertension,* 531  
*Cancer Chemotherapeutic Agents: Handbook of Clinical Data,* 1719  
*Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists,* 823  
*Clinical Interviewing and Counseling: Principles and Techniques,* 1114
- C**
- Calcitonin;** self-medication; costs, effects, clinical pharmacists training programs, inpatients, 1527
- Canrenone;** metabolites; spironolactone, blood levels, following neomycin sulfate, patients, 1701
- Capsules;** phenytoin sodium; stability, storage, counting

machine, spectrometry and colorimetry, 1539  
**Carbenicillin;** infections; combined therapy, granulocytic cancer patients, 178  
**Cardiac drugs**  
 bretylium tosylate; pharmacokinetics, adverse reactions, dosage, interactions, review, 1189  
 digitalis; drug interactions, monitoring, Medicaid patients, 923; interactions, outpatients, monitoring, programs, 653  
 digitoxin; poisoning, antidotes, patients, 92  
 digoxin; interactions, quinidine, increased digoxin blood levels, patient, 968  
 lidocaine hydrochloride; withdrawal, lack, ventricular arrhythmias, myocardial infarction patients, 778  
 pentamethyl tetranitrate; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539  
 propranolol hydrochloride; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539  
 quinidine sulfate; interactions, digoxin, increased blood levels, patients, 968  
**Cardioplegic solutions;** formulations; manufacturing, and quality control, hospital pharmacy, 1361  
**Carts;** pharmaceutical services; decentralized, without satellites, 1513  
**Catheters;** plastic; toxicity, thrombosis, patients, effects, physical characteristics, 1707  
**Cefamandole nafate;** pharmacokinetics; adverse reactions, dosage, effects, review, 1503  
**Cefazolin;** prescriptions; prescribing, control, programs, hospital, 1055  
**Cefazolin sodium**  
 infections; combined therapy, granulocytic cancer patients, 178  
 injections; filters, membrane, effects, concentration and particulate contamination, in sodium chloride and dextrose in water, 657  
**Cefoxitin sodium**  
 incompatibilities; lack, amikacin sulfate, gentamicin sulfate, kanamycin sulfate, tobramycin sulfate and lidocaine hydrochloride, *in vitro*, 33  
 pharmacokinetics; adverse reactions, dosage, effects, review, 1503  
**Cephalexin;** costs; hospitals, and drug use, 1347  
**Cephalothin**  
 costs; hospitals and drug use, 1347  
 toxicity; skin, patients, 609  
**Cephalothin sodium;** infections, combined therapy, granulocytic cancer patients, 178  
**Charcoal activated**  
 adsorption; sucrose, lack, *in vitro*, 797  
 comparison, kaolin, combination, pectin; effects, aspirin absorption, patients, 1097  
 therapy; clonidine, overdose, review, 906  
**Charges;** pharmaceutical services; hospitals, based upon drug cost plus per-diem fees, 355; hospitals, based upon medication administration record, 365; hospitals, based upon per-diem drug costs, 363; hospitals, computerized system using markup and a dose fee, 360  
**Chloramphenicol sodium succinate;** incompatibilities; glycopyrrolate, effects, pH, 508  
**Chloroquine;** sarcoidosis; therapy, discussion, 351  
**Chlorothiazide;** adverse reactions; hyponatremia, patients, 1107  
**Chlorpheniramine maleate;** tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Cholestyramine resa**  
 antidiarrheal; poisoning, digitoxin, patients, 92  
 diarrhea; therapy, discussion, 757  
**Cisplatin;** stability; solutions, UV spectrometry, 38  
**Classified Advertising,** 120, 256, 403, 561, 704, 847, 985, 1125, 1286, 1431, 1604, 1725  
**Clinical Forum,** 89, 230, 674, 806, 968, 1103, 1377, 1561  
**Clinical pharmacists**  
 consultation; patients, family practice office, 912  
 dosage schedules; pharmacokinetics, development and reimbursement, 1523  
 role; patients, diabetes mellitus and hypertension, management, 1321  
 rounds; toxicity, skin, monitoring, hospitals, patients, 609  
 self-medication; role, cost savings, inpatients, 1527  
 workload; drug use review, hypotensive agents, family practice clinic, 1665  
**Clinical pharmacy**  
 aminoglycosides; blood levels, rational therapy, pharmacists, role, 1080  
 anticoagulants; services, ambulatory clinic, 645  
 consultation; poisoning, pediatrics, clinical toxicology service, 1087  
 decentralized; emergency room, costs, 52  
 effects; drug information, services, hospitals, 1520  
 Harvey A. K. Whitney Lecture Award; 1978, 311  
 outpatients; services, survey, 1978, university-affiliated hospitals, 1193  
 parenteral nutrition; therapy, effects, patient outcome and costs, 785

patient information; consultation, deferoxamine, Cooley's anemia patients, 788  
 patients; ambulatory, clinic, screening and prescribing, 916  
 reimbursement; third-party, pharmacokinetic dosage schedules, 1521  
 services; charges, hospitals, based upon drug cost plus per-diem fees, 355; effects, adverse reactions, length of stay, inpatients, 1691; effects, patients' perceptions of health care quality, 325; hospitals, strategy, increased demand, 1553; hospitals, survey, 1978, 316; reimbursement, third-party, models, 1548  
**Clonidine**  
 dosage; overdose, and therapy, review, 906  
 dosage schedules; methodology, pharmacokinetics, and pharmacodynamics, patient individualization, 802  
**Clotrimazole;** mechanism of action; toxicity, dosage, availability and costs, review, 1326  
**Codeine;** diarrhea; therapy, discussion, 757  
**Colchicine;** gout; and hyperuricemia, therapy, discussion, 497  
**Colestipol hydrochloride;** antidotes; poisoning, digitoxin, patients, 92  
**Colorimetry**  
 dosage forms; tablets, and capsules, storage, counting machine, effects on stability, 1539  
 meperidine hydrochloride; dosage forms, adulteration, 1094  
**Combined therapy**  
 amikacin and ticarcillin; toxicity, ear, leukopenic patients, 1083  
 gentamicin and ticarcillin; toxicity, ear, leukopenic patients, 1083  
 netilmicin and ticarcillin; toxicity, ear, leukopenic patients, 1083  
 ticarcillin and amikacin, gentamicin or netilmicin; toxicity, ear, leukopenic patients, 1083  
**Concentration**  
 amino acids; parenteral nutrition, solutions, formulary change, hospitals, 57  
 cefazolin sodium; injections, effects, membrane filters, in sodium chloride and dextrose in water, 657  
 insulin; availability, effects, low-dose continuous injections, 330  
**Containers**  
 cefoxitin sodium; effects, on stability, additives, 33  
 heparin; solutions, use, collection of body cavity fluids, 211  
 insulin; injections, continuous low-dose, effects, glass and polyvinyl chloride, 330  
 nitroglycerin; plastics, and glass, extemporaneous, i.v. injections, stability, 173  
 plastics; admixtures, injections, dextrose, *in vitro*, compounding times and contamination rates, 513; incompatibilities, diazepam, i.v., in dextrose, sodium chloride, Ringer's injection and Ringer's injection lactated, 505  
**Contamination**  
 admixtures; injections, during sterility testing, 1493; injections, plastic containers, dextrose in water, 513  
 injections; i.v., comparison, systems, 1497; i.v., effects of membrane final filter pore size on survival, rabbits, 1711; i.v., phlebitis, effects, inline membrane final filters, postoperative patients, 1355  
 microbiological; injections, and administration sets, determination, membrane filter set, 1202; solutions, protein hydrolysates and dextrose, prevention, sodium acetate, 1672  
 particles; cefazolin sodium, injections, in sodium chloride and dextrose in water, 657  
**Contraceptives, oral**  
 mestranol, combination, norethindrone; ischemic bowel disease, patient, 1103  
 norethindrone, combination, mestranol; ischemic bowel disease, patient, 1103  
**Control**  
 inventory; hospital pharmacy, computerized system, 360  
 prescribing; cefazolin, programs, hospital, 1055  
 purchasing; drugs, and inventory, hospitals, U.S., General Accounting Office report, 1171  
**Control, quality** see also **Quality assurance**  
**Correction Notices,** 305, 600, 745, 1050, 1166, 1660  
 Bretylium tosylate: A review (Sep 1979), 745  
 Compatibility and stability of electrolytes, vitamins and antibiotics in combination with 8% amino acid solution (Jan 1978), 600  
 Compatibility of glycopyrrolate injection with commonly used infusion solutions and additives (Apr 1979), 745  
 Physicochemical determinants of incompatibility and instability in injectable drug solutions and admixtures (Oct 1978), 305  
 Proceedings of the 30th Annual Session of the ASHP House of Delegates (Jul 1979), 1166  
 Roster of residents in training programs accredited by the American Society of Hospital Pharmacists—calendar year 1978 (May 1979), 1050

**Costs**  
 alumin; prescribing, drug use review, hospitals, 1205  
 amikacin; pharmacists, hospital, monitoring, 1209  
 antibiotics; rational therapy, hospitalized pyelonephritis patients, 1334  
 anti-infective agents; rational therapy, hospitalized pyelonephritis patients, 1334  
 computers; hospital pharmacy, development of multi-functional drug file, 1197  
 drug information; systems, evaluation, 793  
 drug use review; hypotensive agents, comparison, methods, family practice clinic, 1665  
 drugs; effects, decentralized operating room pharmacy services, 1342; records, use in developing drug use profiles, hospitals, 1347  
 education; patients, adrenalectomy, hospital pharmacists, 1212  
 fungicides; discussion, 1326  
 heparin; effects, dosage schedules, based upon pharmacokinetics, 920  
 injections; i.v., comparison, systems, 1497  
 parenteral nutrition; decreased, formulary change in amino acid concentration, 57; therapy, pharmacists, role, 785  
 pharmaceutical services; decentralized, without satellites, 1513; hospitals, based upon drug cost plus per-diem fees, 355  
 pharmacokinetics; services, hospitals, 368  
 pharmacology; services, decentralized, emergency room, 52  
 reprints; journals, articles, 1219  
 self-medication; inpatients, decreased, clinical pharmacists, role, 1527  
 tobramycin; pharmacists, hospital, monitoring, 1209  
**Coumarin derivatives;** drug interactions; monitoring, Medicaid patients, 923  
**m-Cresol;** preservatives; effects, adulteration tests on meperidine hydrochloride, 1094  
**Current Literature,** 96, 241, 381, 522, 686, 817, 972, 1112, 1237, 1410, 1570, 1714  
**Cytarabine;** self-medication; costs, effects, clinical pharmacists training programs, inpatients, 1527

## D

**Deferoxamine;** patient information; pharmacists, hospital, consultation, Cooley's anemia patients, 788  
**de Haen Drugs in Use;** drug information; comparison, other services, 1215  
**Deserpine;** drug interactions; monitoring, Medicaid patients, 923  
**Dexamethasone;** self-medication; patients, adrenalectomy, education, by hospital pharmacists, 1212  
**Dexamethasone sodium phosphate;** incompatibilities, glycopyrrolate, effects, pH, 508  
**Dextran 70;** adverse reactions; mechanism of action, thrombotic thrombocytopenic purpura patient, 89  
**Dextrose**  
 additives; cefazolin sodium, effects, membrane filters, on concentration and particle contamination, 657; injections, diazepam, i.v., incompatibilities, plastics, 505  
 admixture; injections, plastic containers, compounding times and contamination rates, 513  
 adulteration; meperidine hydrochloride, dosage forms, alone and with sodium chloride; solutions, effects, insulin availability, low-dose continuous injections, 330  
 diluents; effects, stability, extemporaneous nitroglycerin i.v. injections, 173  
 and FeraMines II; additives, stability, incompatibilities, 511  
 heparin sodium; stability, 618  
 injections; contamination, microbiological, determination, membrane filter set, 1202  
 parenteral nutrition; adverse reactions, due to fat-free content, patient, 230  
 solutions; osmolarity, methods, 1357; sodium acetate, preservatives, 1672  
**Diagnosis;** hemolytic; effects, naproxen blood levels, patients, 1567  
**Diazepam**  
 costs; hospitals and drug use, 1347  
 incompatibilities; glycopyrrolate, effects, pH, 508;  
 plastics, i.v., in dextrose, sodium chloride, Ringer's injection and Ringer's injection lactated, 505  
 tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Digitalis**  
 drug interactions; monitoring, Medicaid patients, 923  
 interactions; diuretics, monitoring, programs, outpatients, 653  
**Digitoxin;** poisoning; antidotes, patients, 92  
**Digoxin;** interactions; hydrochlorothiazide, monitoring, programs, outpatients, 653  
 quinidine, increased digoxin blood levels, patient, 968  
**Diluents**  
 dextrose; effects, stability, extemporaneous nitroglycerin

- i.v. injections, 173  
sodium chloride; effects, stability, extemporaneous nitroglycerin i.v. injections, 173
- Dimenhydrinate;** incompatibilities; glycopyrrolate, effects, pH, 504
- Diphenoxydate;** diarrhea; therapy, discussion, 757
- Dipyridamole;** purpura; thrombotic thrombocytopenic, therapy, patient, 89
- Disaster planning;** hospital pharmacy; personnel, role, 1337
- Disintegration;** dosage forms; tablets, and capsules, counting machine, effects on stability, spectrometry and colorimetry, 1539
- Dissolution;** dosage forms; tablets, and capsules, counting machine, effects on stability, spectrometry and colorimetry, 1539
- Diuretics;** chlorothiazide; hyponatremia, patients, 1107  
furosemide; dosage schedules, comparison, once and twice daily, excretion, patients, 68  
interactions; digitalis, monitoring, programs, outpatients, 653  
Reye's syndrome; therapy, review, 767  
spironolactone; availability, effects, neomycin sulfate, patients, 1701; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539
- Dopamine;** injections; therapy, clonidine overdose, review, 906
- Dosage;** albumin; rational therapy, hospitals, 1205  
amphotericin B; review, 1326  
anticoagulants; monitoring, pharmacists, hospital, 214  
bretium tosylate; review, 1189  
butorphanol tartrate; review, 1683  
cefamandole nafate; review, 1503  
cefoxitin sodium; review, 1503  
clonidine; overdose, and therapy, review, 906  
clotrimazole; review, 1326  
flucytosine; review, 1326  
gentamicin; relation, blood levels, ascitic patients, 1704  
griseofulvin; review, 1326  
insulin; low, injections, continuous availability, effects of solution type, container, administration set, concentration and rate, 330  
methenamine hippurate; review, 1509  
methenamine mandelate; review, 1509  
miconazole nitrate; review, 1326  
nalidixic acid; review, 1071  
nystatin; review, 1326  
oxolinic acid; review, 1077  
steroids, cortico-; education, adrenalectomy, patients, by hospital pharmacists, 1212  
theophylline; oral, using clearance rates following i.v. infusion, patients, 66  
warfarin sodium; methodology, prothrombin time, patients, 1351
- Dosage forms;** aminophylline; tablets, comparison, sustained-action theophylline tablets, patients, 613  
meperidine hydrochloride; adulteration, visual, colorimetry and UV spectrometry, 1094  
theophylline; sustained-action, comparison, regular aminophylline tablets, patients, 613
- Dosage schedules;** amikacin; pharmacists, hospital, role, 1209  
aminoglycosides; computers, costs, hospitals, 368  
aminophylline; tablets, comparison, sustained-action theophylline tablets, patients, 613  
furosemide; comparison, once and twice daily, excretion, patients, 68  
heparin; pharmacokinetics, effects, costs, tests and errors, 920  
hypotensive agents; methodology, pharmacokinetics, and pharmacodynamics, patient individualization, 802; pharmacokinetics, discussion, 1222  
lidocaine hydrochloride; withdrawal, lack, ventricular arrhythmias, myocardial infarction patients, 778  
pharmacokinetics; clinical pharmacists, development and reimbursement, 1523  
theophylline; sustained-action, comparison, regular aminophylline tablets, patients, 613; tablets, sustained-action, blood levels, asthmatic children, 1698  
tobramycin; pharmacists, hospital, role, 1209
- Doxorubicin hydrochloride;** injections; stability, effects, temperature, 1536
- Drug administration;** education, pharmaceutical; internships, students, 791  
hospitals; effects, adverse reactions, length of stay, inpatients, 1691  
injections; flow, rates, models, 338; i.v., flow rates, clamps, comparison, electronic controller, 1090  
self-medication; clinical pharmacists, role, cost savings, inpatients, 1527; deferoxamine, Cooley's anemia patients, role of hospital pharmacist, 788; dexamethasone, adrenalectomy patients, role, hospital pharmacists, 1212
- Drug distribution systems;** hospitals; effects, adverse reactions, length of stay, inpatients, 1691
- patients, 1691  
unit dose; carts, decentralized pharmaceutical service without satellites, 1513; hospitals, survey, 1978, comparison, 1975, 316
- Drug information;** admixture services; injections, manuals, development, review, 517  
anticoagulants; pharmacists, hospital, bulletin, 214  
parenteral nutrition; manuals, development, review, 517  
services; clinical pharmacy, effects, hospitals, 1520; comparison, 1215  
systems; evaluations, method, 793
- Drug interactions;** aluminum hydroxide, combination, magnesium hydroxide and aminophylline; lack, effects, absorption, patients, 1059  
aminoglycosides and cephalothin sodium; toxicity, kidney, granulocytic cancer patients, 178  
aminophylline and aluminum hydroxide, combination, magnesium hydroxide; lack, effects, absorption, patients, 1059  
antacids and tetracycline; monitoring, programs, outpatients, 653  
aspirin and phenothiazines; potentiation, review, 633  
bretium tosylate; review, 1189  
cephalothin sodium and aminoglycosides; toxicity, kidney, granulocytic cancer patients, 178  
digitalis and diuretics; monitoring, programs, outpatients, 653  
digoxin and hydrochlorothiazide; monitoring, programs, outpatients, 653  
digoxin and quinidine sulfate; blood levels, digoxin, increased, patient, 968  
diuretics and digitalis; monitoring, programs, outpatients, 653  
drugs, nonprescription; monitoring, programs, outpatients, 653  
hydrochlorothiazide and digoxin; monitoring, programs, outpatients, 653  
information; systems, evaluation, 793  
meperidine and phenothiazines; potentiation, review, 633  
monitoring; patients, Medicaid, 923; programs, ambulatory outpatients, based upon medical-record review, patient interviews and laboratory-test evaluations, 653  
morphine sulfate and phenothiazines; potentiation, review, 633  
nalidixic acid; review, 1071  
neomycin sulfate and spironolactone; effects, spironolactone availability, patients, 1701  
phenothiazines and aspirin, meperidine and morphine sulfate; potentiation, review, 633  
quinidine sulfate and digoxin; blood levels, digoxin, increased, patient, 968  
spironolactone and neomycin sulfate; effects, spironolactone availability, patients, 1701  
sulfamethoxazole, combination, trimethoprim; review, 893  
trimethoprim, combination, sulfamethoxazole; review, 893
- Drug Reaction Alerts,** 96, 243, 383, 522, 694, 821, 975, 1112, 1237, 1413, 1573, 1716
- Drug Regulation Review Act of 1978;** laws; provisions, Kennedy bill, 1230
- Drug Therapy Reviews,** 342, 351, 497, 622, 757, 893, 1071, 1077, 1186, 1326, 1503, 1683
- Drug use;** toxicity; skin, patients, hospitals, 609
- Drug use review;** amikacin; pharmacists, hospital, 1209  
antibiotics; hospitals, systems, problems, 376; prescribing, effects, length of hospital stay, pyelonephritis patients, 1334  
anti-infective agents; prescribing, effects, length of hospital stay, pyelonephritis patients, 1334  
cefazolin; prescribing, control, programs, hospital, 1055  
effects; rational therapy, discussion, 1099  
heparin sodium and warfarin sodium; pharmacists, hospital, embolism, thrombosis and thrombophlebitis, 214  
hospital pharmacy; computers, use, 1197  
hospitals; effects, drug-charge records, 1347  
hypotensive agents; comparison, methods, family-practice clinic, 1665  
interactions; monitoring, Medicaid patients, 923  
pharmacist involvement; hospitals, survey, 1978, comparison, 1975, 316  
tobramycin; pharmacists, hospital, 1209  
warfarin sodium and heparin sodium; pharmacists, hospital, embolism, thrombosis and thrombophlebitis, 214
- Drug utilization review;** see **Drug use review**
- Drug withdrawal;** lidocaine hydrochloride; lack, ventricular arrhythmia, myocardial infarction patients, 778
- Drugs;** selection; erythromycin, and derivatives, review, 1185
- therapy; methodology, systematic problem-solving approach, 798
- Drugs, adverse reactions;** allopurinol; allergies, patients, 1377  
amikacin; monitoring, pharmacists, hospital, 1209  
amino acids; rash, due to fatty-acid deficiency, patient, 230  
bretium tosylate; review, 1189  
cefamandole nafate; review, 1503  
cefoxitin sodium; review, 1503  
chlorothiazide; hyponatremia, patients, 1107  
dextran 70; mechanism of action, thrombotic thromboctopenic purpura patient, 89  
dextrose; solutions, due to fat-free content, patient, 230  
erythromycin; and derivatives, review, 1185  
folic acid; allergies, patient, 1565  
heparin; thrombopenia, patients, 1561  
hospitals; effects, drug distribution systems, drug administration systems, drug administration and clinical pharmacy services, inpatients, 1691  
iatrogenic diseases; skin, monitoring, hospitals, patients, 609  
lidocaine hydrochloride; lack, ventricular arrhythmia, upon withdrawal, myocardial infarction patients, 778  
mestranol, combination, norethindrone; ischemic bowel disease, patient, 1103  
methenamine hippurate; review, 1509  
methenamine mandelate; review, 1509  
monitoring; computers, programs, hospitalized patients, 198  
nalidixic acid; review, 1071  
norethindrone, combination, mestranol; ischemic bowel disease, patient, 1103  
oxolinic acid; review, 1077  
parenteral nutrition; solutions, fat-free, patient, 230  
phenothiazines; review, 633  
pneumococcal vaccines; review, 773  
sulfamethoxazole, combination, trimethoprim; review, 893  
thioridazine; hyperpyrexia, schizophrenic patient, 674  
tobramycin; monitoring, pharmacists, hospital, 1209  
tolbutamide; hyponatremia, patients, 1107  
trimethoprim, combination, sulfamethoxazole; review, 893
- Drugs, availability;** aminophylline; tablets, comparison, sustained-action theophylline tablets, patients, 613  
amphotericin B; review, 1326  
aspirin; effects, charcoal activated, comparison, kaolin, combination, pectin, patients, 1097  
clotrimazole; review, 1326  
flucytosine; review, 1326  
griseofulvin; review, 1326  
information; services, comparison, 1215  
insulin; injections, low-dose, continuous, effects of solution type, container, administration set, concentration and rate, 330  
miconazole nitrate; review, 1326  
nystatin; review, 1326  
spironolactone; effects, neomycin sulfate, patients, 1701  
theophylline; tablets, sustained-action, comparison, regular aminophylline tablets, patients, 613
- Drugs, body distribution;** gentamicin; acitic patients, 1704  
naproxen; effects, hemodialysis, patients, 1567
- Drugs, clinical effectiveness;** aminophylline; tablets, comparison, sustained-action theophylline tablets, patients, 613  
theophylline; sustained-action, comparison, regular aminophylline tablets, patients, 613
- Drugs, nonprescription;** interactions; monitoring, programs, outpatients, 653
- Dyphylline;** pharmacokinetics; patients, 1179

## E

- Economics;** hospital pharmacy; purchasing, and inventory, statistics, 1978 survey, 650
- Editorials,** 31, 169, 170, 307, 308, 455, 603, 747, 891, 1053, 1169, 1319, 1489, 1490, 1663
- Administrative direction for clinical practice, 308
- The ASHP SIGs: Sound beginning, promising future, 1169
- Contamination: Lost or found? 1489
- The decline and fall of secundum artem, 1053
- Economics of hospital pharmacy practice, i: Third-party reimbursement, 169; ii: Charging for services, 307
- Expiration dates of repackaged drug products, 170
- Hospital cost containment and the pharmacist, 31
- On the road to assuring competence, 747
- Pharmaceutical marketing: New rules for an old game, 603
- Rationing hospital services, 1319
- Reviewing the 1970s: The American Society of Hospital Pharmacists, 1663

**Reviewing the 1970s:** Hospital pharmacy practice, 1490  
**Underpriced ASHP membership dues:** Long-range folly?, 891

**The written word,** 455

#### **Education**

anticoagulants; patients, ambulatory, clinic, pharmacists, hospital, role, 645  
 nurses; continuing, one-day program, by pharmacists, 44  
 outpatients; survey, 1978, university-affiliated hospitals, 1193  
 patients; adrenalectomy, by hospital pharmacists, 1212; warfarin, hospitals, pharmacists and nurses, 219; theophylline, audiovisual, with and without pharmacists present, 63  
 personnel; admixtures, injections, control, quality, 605  
 physicians; antibiotics, aminoglycosides, by hospital pharmacists, 1209

#### **Education, pharmaceutical**

American Society of Hospital Pharmacists; topics, 1967-1978, Midyear Clinical Meeting papers, 1372  
 continuing; hospital pharmacy, decentralized, staff program, 50  
 internships; students, emphasis on nursing assistant and medication administration through nursing service, 791  
 residences; hospitals, screening and selection procedure, 194  
 technicians; programs, training, 1533

**Electrolytes;** solutions; osmolarity, methods, 1357  
**Emetics;** ipecac; effects, electrolyte blood levels, comparison, lavage patients, 1366

#### **Equipment**

administration sets; electronic, comparison, clamps, i.v. flow rates, 1090; models, flow rates, 338  
 clamp; flow rates, i.v. injections, comparison, electronic controller, 1090  
 counting machines; storage, tablets, and capsules, effects on stability, 1539  
 hospital pharmacy; word-processing machines, compared, 1529  
 injections; i.v., comparison, systems, contamination, costs and workload, 1497

**Equipment and Supplies,** 114, 555, 1119, 1599  
 Abbott Laboratories, infusion pumps, 115; pump sets, 1122

American Optical Corporation, refractometer, 1123  
 Apex Medical Supply, Inc., educational materials, 1124; medicine dropper, 116

Barnstead Company, NANOpure system, 116  
 Baxa Corporation, bottle adapter, 115; oral liquid dispenser, 555

Burleson Airology Corporation, laminar-flow workstation, 1119

Burrone Medical Products, administration sets, 115; double-filtered i.v. set, 559; filter needle, 1122; primary additive i.v. set, 1122

Cormed, Inc., mobile infusion pumps, 1599  
 Corning Glass Works, pH meter, 558

Cosa Corporation, deionizer, 1599  
 Draster, Inc., drug-control systems, 1600; punch-card system, 1124

Dycem Limited, contamination-control mats, 1122

General Computer Corporation, hardware/software package, 116

Greene Pharmaceutical Instruments B.V., suppository machine, 1603

Healthmark Industries Co., autoclavable plastic bags, 114; autoclavable plastic trays, 1603; sterilizing tray, 1123; tote boxes, 560

Hierath & Andrews Corp., weighing system, 1119

IMED Corporation, equipment pole, 558; volumetric infusion pump, 116

IVAC Corporation, volumetric infusion pump, 1123

Jobar Corporation, catalog, 560

Kaymont Consolidated Industries, Inc., humidity-measuring instrument, 116

Lerner Packaging, brochure, 1124

Marvel Division, Dayton-Walther Corporation, refrigerators, 1599

McGraw Laboratories, PDI system, 559

Medi-Dose, Inc., lid-labels, 559

Herman Miller, Inc., Co/Struc System, 116

Millipore Corporation, Addi-Chek system, 115; disposable filter unit, 1600

Modern Controls, Inc., blister-pack leak tester, 1600; bottle-leak tester, 1122

New England Applied Research, radiopharmaceutical analyzer, 1600

NCR Corporation, software package, 114

Fall Trinity Micor Corporation, brochure, 560

Parke, Davis & Company, laminar flow hood, 1599; medication cart, 1119; medication-control module, 555; night cabinet, 114

Penco Products, Inc., laboratory shelving, 115

Polyfoam Packers Corporation, catalog, 1124; containers, 556

RC Smith Company, modular furniture, 1122

RX Tool Company, cap remover, 558  
 Sigmamotor, Inc., infusion pump, 1122  
 Spacesaver Corporation, brochure, 560  
 Storx Corporation, catalog, 560

Telco International Corporation, security system, 555  
 Testing Machines Inc., testing devices, 1600  
 United Utensils, Co., Inc., bracket, 555

Wave Energy Systems, Inc., brochure, 560

Wheaton Instruments, dispenser, 115; Unispense, 560

Whitman Medical Corporation, i.v. stabilizer, 1600

**Equivalency**

aminophylline; tablets, comparison, sustained-action theophylline tablets, patients, 613  
 theophylline; tablets, sustained-action, comparison, regular aminophylline tablets, patients, 613

**Equivalency, generic**

aluminum hydroxide, combination, magnesium hydroxide, simethicone; tablets, acid reactivity, in vitro, 660  
 magnesium hydroxide, combination, aluminum hydroxide, simethicone; tablets, acid reactivity, in vitro, 660  
 simethicone, combination, aluminum hydroxide, magnesium hydroxide; tablets, acid reactivity, in vitro, 660

**Errors, medication**

albumin; prescribing, hospitals, 1205  
 heparin; effects, dosage schedules, based upon pharmacokinetics, 920

injections; i.v. flow rates, clamps, comparison, electronic controller, 1090  
 omission; compliance, heparin sodium and warfarin sodium, monitoring, hospital pharmacists, 214; compliance, patients, diabetes mellitus and hypertension, clinical pharmacists, role, management, 1321

**Erythromycin;** and derivatives; mechanism of action, pharmacokinetics, adverse reactions, rational therapy, review, 1185  
**Estrogens;** rational therapy; patients, peri- and postmenopausal, review, 1062

**Excretion**

aspirin; urinary, effects, charcoal activated, comparison, kaolin, combination, pectin, patients, 1097  
 dypheylline; patients, 1179  
 furosemide; dosage schedules, determination, once and twice daily, patients, 68

lidocaine hydrochloride; withdrawal, lack, ventricular arrhythmia, myocardial infarction patients, 778  
 spiranonolactone; urinary, effects, neomycin sulfate, patients, 1701  
 theophylline dosage, oral, using clearance rates following i.v. aminophylline infusion, patients, 66

**Extrapyramidal disorders;** antiparkinson agents; prophylaxis, psychotherapeutic agent-induced, patients, 641

## F

**Filters;** membrane; air-venting, effects, air flow, administration sets, 749; contamination, microbiological, determination, injections and administration sets, 1202; inline, final, pore size, effects, survival following infusion of contaminated i.v. fluids, rabbits, 1711; inline therapy, effects, phlebitis, postoperative patients, 1355

**Flavours;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients, 1565

**Food and Drug Administration (U.S.);** regulations; package inserts, patients, pharmacist's responsibility, 226

**Flavors;** sucrose; adsorption, charcoal activated, lack, in vitro, 797

**Flow;** rates; administration sets, models, 338; injections, i.v., clamp, comparison, electronic controller, 1090; insulin, injections, continuous low-dose, effects on availability, 330

**Flucytosine;** mechanism of action; toxicity, dosage, availability and costs, review, 1326

**Folic acid;** allergies; patients

drugs; charges based upon medication administration record, 365; costs, use in developing drug-use profiles, 1347; purchasing, and inventory, U.S., General Accounting Office report, 1171  
 drugs, adverse reactions; length of stay, effects, drug distribution systems, drug administration and clinical pharmacy services, inpatients, 1691  
 pharmaceutical services; costs, based upon drug cost plus per-diem fees, 355; costs, pricing, computerized system using a markup and a dose fee, 360; pricing, systems, per-diem, 363  
 rational therapy; prescribing, effects, length of stay, pyelonephritic patients, 1334  
**Hours**; 24-hour service; dosage schedules, pharmacokinetics, role, clinical pharmacists, 1523; hospital pharmacy, survey, 1978, comparison, 1975, 316; outpatients, 1978 survey, university-affiliated hospitals, 1193  
**Hydralazine hydrochloride**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Hydrochlorothiazide**; interactions; digoxin, monitoring, programs, outpatients, 653  
**Hydrogen ion concentration**  
 cefazolin sodium; injections, effects, membrane filters, in sodium chloride and dextrose in water, 657  
 cefotaxime sodium; effects, stability, additives, injections, 33  
 cisplatin; effects, stability, solutions, 38  
 effects; glycopyrrolate, additives, stability, 508  
 FreAmine II; decreased, by tetracycline additive, 511  
 heparin sodium; effects, stability, in dextrose in water and dextrose in sodium chloride, 618  
**Hyperalimentation**, see **Parentral nutrition**  
**Hypotensive agents**  
 clonidine; overdose, and therapy, review, 906  
 deserpine; drug interactions, monitoring, Medicaid patients, 923  
 dosage schedules; methodology, pharmacokinetics, and pharmacodynamics, patient individualization, 802; pharmacokinetics, discussion 1222  
 drug use review; comparison, methods, family-practice clinic, 1665  
 guanethidine; drug interactions, monitoring, Medicaid patients, 923  
 hydralazine hydrochloride; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539  
 methyldopa; drug interactions, monitoring, Medicaid patients, 923; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539  
 patients, clinical pharmacists, role, management, 1321  
 rawwolffia serpentina; extracts, drug interactions, monitoring, Medicaid patients, 923  
 reserpine; drug interactions, monitoring, Medicaid patients, 923  
 reserpine; drug interactions, monitoring, Medicaid patients, 923

**Immunosuppressive agents**; azathioprine; polychlorodrugs, relapsing, therapy, patient, 806  
**Incompatibilities**  
 additives and FreAmine II; discoloration, and precipitation, 511  
 additives and glycopyrrolate; effects, pH, 508  
 amphotericin and FreAmine II; discoloration, and precipitation, 511  
 ampicillin sodium and FreAmine II; discoloration, and precipitation, 511  
 diazepam and glycopyrrolate; effects, pH, 508  
 diazepam and plastics; injections, i.v., in dextrose, sodium chloride, Ringer's injection and Ringer's injection lactated, 505  
 dimenhydrinate and glycopyrrolate; effects, pH, 508  
 FreAmine II and additives; discoloration, and precipitation, 511  
 glycopyrrolate and additives, effects, pH, 508  
 methoheptenium sodium and glycopyrrolate; effects, pH, 508  
 pentazocine lactate and glycopyrrolate; effects, pH, 508  
 pentobarbital sodium and glycopyrrolate; effects, pH, 508  
 plastics and diazepam; injections, i.v., in dextrose, sodium chloride, Ringer's injection, and Ringer's injection lactated, 505  
 Ringer's injection lactated and glycopyrrolate, effects, pH, 508  
 secobarbital sodium and glycopyrrolate; effects, pH, 508  
 sodium bicarbonate and glycopyrrolate; effects, pH, 508

sucrose and charcoal activated; adsorption, sodium saicylate, reduced, in vitro, 797  
 tetracycline hydrochloride and FreAmine II; discoloration, and precipitation, 511  
 thiopental sodium and glycopyrrolate; effects, pH, 508  
**Index Medicus**; drug information; comparison, other services, 1215

**Indomethacin**; gout; and hyperuricemia, therapy, discussion, 497

**Industry, pharmaceutical**; drugs; storage, and stability, use of lot numbers, 1545

**Information**; reprints; requests, response rates, 1219

**Injections**

cefazolin sodium; filters, membrane, effects, concentration and particulate contamination, in sodium chloride and dextrose in water, 657

diazepam; i.v. incompatibilities, plastics, in dextrose, sodium chloride, Ringer's injection and Ringer's injection lactated, 505

doxorubicin hydrochloride; stability, effects, temperature, 1536

filters, membrane, inline, air-venting, effects, air flow, administration sets, 749

heparin; rates, methodology, comparison, pharmacokinetic model and patient weight, 782

heparin sodium; vehicles, stability, dextrose in water or sodium chloride, 618

insulin; dosage, low, continuous, availability, effects of solution type, container, administration set, concentration and rate, 330

intravenous; contamination, admixtures, during sterility testing, 1493; contamination, effect, membrane final-filter pore size on survival, rabbits, 1711; contamination, microbiological, determination, membrane filter set, 1202; equipment, comparison, systems, contamination, costs and workload, 1497; flow, rates, clamps, comparison, electronic controller, 1090; osmolarity, methods, 1357; phlebitis, effects, inline membrane final filters, postoperative patients, 1355

nitroglycerin; i.v. extemporaneous, stability, 173

**Insulin**; availability; injections, low-dose, continuous, effects of solution type, container, administration set, concentration and rate, 330

**Interactions**; tetracycline and antacids; monitoring, progress, outpatients, 653

**International Pharmaceutical Abstracts**; drug information; comparison, other services, 1215

**Intravenous therapy**; toxicity; phlebitis, effects, inline membrane final filters, postoperative patients, 1355

**Inventory**

control; hospital pharmacy, computerized system, 360  
 drugs; hospitals, U.S., General Accounting Office report, 1171

hospital pharmacy; computers, use, 1197; drugs, storage and stability, use of lot numbers, 1545; effects, decentralized operating room pharmaceutical services, 1342; statistics, 1978 survey, 650

**Ions** stannous; stability, stannous chloride dihydrate, comparison, commercial and extemporaneous radiopharmaceutical kits, 1370

**Iowa Drug Information Service**; drug information; comparison, other services, 1215

**Ipecac**; effects; electrolytes, blood levels, comparison, lavage patients, 1336

## J

**Journal References**, 96, 241, 381, 522, 686, 817, 972, 1112, 1237, 1410, 1570, 1714

**Journals**; articles; reprints, requests, response rates, 1219

## K

**Kanamycin sulfate**; incompatibilities; cefotaxime sodium, lack, in vitro, 33

**Kaozin**; combination, pectin; comparison, charcoal activated, effects, aspirin absorption, patients, 1097

diarrhea; therapy, discussion, 757

**Kinetics**

amoxicillin trihydrate; stability, temperature, effects, reconstituted unit dose, 209

ampicillin; stability, temperature, effects, reconstituted unit dose, 209

penicillin V potassium; stability, temperature, effects, reconstituted unit dose, 209

## L

**Lactobacillus acidophilus**

combination, *Lactobacillus bulgaricus*; prophylaxis, ampicillin-induced diarrhea, patients, 754

diarrhea; therapy, discussion, 757

**Lactobacillus bulgaricus**; combination, *Lactobacillus acidophilus*; prophylaxis, ampicillin-induced diarrhea, patients, 754

**Law Notes**, 85, 226, 1230

**Laws**

Drug Regulation Reform Act of 1979; provisions, Kennedy bill, 1230

pharmacy; inspections, warrantless, discussion, 85

**Legislation**; drugs; purchasing, and inventory, hospitals, U.S., General Accounting Office report, 1171

**Letters**, 22, 151, 295, 440, 593, 736, 881, 1024, 1155, 1300, 1464, 1651

**Levamisole hydrochloride**; sarcoidosis; therapy, discussion, 351

**Lidocaine hydrochloride**

antidotes; poisoning, digitoxin, patients, 92

incompatibilities; cefotaxime sodium, lack, in vitro, 33

withdrawal; lack, ventricular arrhythmia, myocardial

infarction patients, 778

**Light**; cisplatin; stability, solutions, 38

**Literature**

American Society of Hospital Pharmacists; topics, 1967-1978, Midyear Clinical Meeting papers, 1372

journals; articles, reprints, response rates, 1219

**Lithium carbonate**; information; comparison, services, 1215

**Loperamide**; diarrhea; therapy, discussion, 757

## M

**Magnesium hydroxide**

combination, aluminum hydroxide; absorption, oral aminophylline, effects, patients, 1059

combination, aluminum hydroxide, simethicone; tablets, equivalence, generic, acid reactivity, in vitro, 660

**Mannitol**; Reye's syndrome; therapy, review, 767

**Manpower**; pharmacists, hospital; outpatients, services, 1978 survey, university-affiliated hospitals, 1193

**Manufacturing**

admixture; injections, plastic containers, dextrose in water, time studies, contamination rates, 513

cardioplegic solutions, hospital pharmacy, 1361

drugs; industry, pharmaceutical, storage, and stability, hospital pharmacy, use of lot numbers, 1545

nitroglycerin; hospital pharmacy, i.v. formulation stability, 173

**Mechanism of action**

amphotericin B; review, 1326

clotrimazole; review, 1326

dextran 70; adverse reactions, thrombotic thrombocytopenic purpura patient, 89

digoxin and quinidine sulfate; blood levels, digoxin, increased, patient, 968

erythromycin; and derivatives, review, 1185

fluconazole; review, 1326

griseofulvin; review, 1326

heparin; thrombopenia, patients, 1561

methenamine hippurate; review, 1509

methenamine mandelate; review, 1509

miconazole nitrate; review, 1326

nalidixic acid; review, 1071

nitrofurantoin; review, 342

nystatin; review, 1326

oxolinic acid; review, 1077

sulfamethoxazole, combination, trimethoprim; review, 893

trimethoprim, combination, sulfamethoxazole; review, 893

**MEDLINE**; drug information; comparison, other services, 1215

**Meeting Dates**, 113

**Meperidine**; interactions; phenothiazines, potentiation, review, 633

**Meperidine hydrochloride**

dose forms; adulteration, visual, colorimetry and UV spectrometry, 1094

hyperpyrexia; therapy, thioridazine-induced, schizophrenia patient, 674

**Mestranol**; combination, norethindrone; ischemic bowel disease, patient, 1103

**Metabolism**; spironolactone; metabolites, canrenone, blood levels, following neomycin sulfate, patients, 1701

**Metaraminol bitartrate**; hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674

**Methenamine hippurate**; mechanism of action; pharmacokinetics, effects, adverse reactions, dosage, review, 1509

**Methenamine mandelate**; mechanism of action; pharmacokinetics, effects, adverse reactions, dosage, review, 1509

**Methicillin**; toxicity, skin, patients, 609

**Methodology**

aminoglycosides; blood levels, rational therapy, pharmacists, role, 1080

antibiotics; drug use review, hospitals, systems, problems, 376

contamination; microbiological, determination, i.v. injections and administration sets, 1202  
drug information; systems, evaluation, 793  
drug interactions; outpatients, monitoring, programs, 653  
drug use review; hypotensive agents, family-practice clinic, 1665  
drugs; stability, hospital pharmacy, use of lot numbers, 1545; therapy, systematic problem solving approach, 798  
furosemide; dosage schedules, comparison, once and twice daily, excretion, patients, 68  
heparin; injections, rates, comparison, patient weight and pharmacokinetic model, 782  
hypotensive agents; dosage schedules, patient individualization, pharmacokinetics, and pharmacodynamics, 802; dosage schedules, pharmacokinetics, discussion, 1222  
patient information; profile development, from drug-discharge records, hospitals, 1347  
prescribing; physicians, rational therapy, discussion, 1099  
theophylline; dosage, oral, using clearance rates following i.v. infusion, patients, 66  
warfarin sodium; dosage, prothrombin time, patients, 1351

**Methohexitol sodium;** incompatibilities; glycopyrrolate, effects, pH, 508

**Methotrexate;** sarcoidosis; therapy, discussion, 351

**Methyldopa;** drug interactions; monitoring, Medicaid patients, 923  
tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539

**Miconazole nitrate;** mechanism of action; toxicity, dosage availability and costs, review, 1326

**Minoxidil;** dosage schedules; methodology, pharmacokinetics, and pharmacodynamics, patient individualization, 802

**Models**  
administration sets; flow, rates, 338  
dipyridine; pharmacokinetics, patients, 1179  
pharmacokinetics; heparin, methodology, injection rates, 782  
reimbursement; clinical pharmaceutical services, third-party, 1548

**Moisture;** dosage forms; tablets, and capsules, counting machine, effects on stability, spectrometry and colorimetry, 1539

**Morphine;** diarrhea; therapy, discussion, 757

**Morphine sulfate;** interactions; phenothiazines, potentiation, review, 633

**Mydratins;** homatropine hydrobromide; solutions, ophthalmic, polycondensation, relapsing, therapy, patients, 806

**N**

**Nalidixic acid;** mechanism of action; pharmacokinetics, interactions, dosage, adverse reactions, review, 1071

**Naproxen** blood levels; hemodialysis, effects, patients, 1567

**Neomycin sulfate;** effects; spironolactone, availability, patients, 1701

**Netilmicin;** and ticarcillin; toxicity, ear, leukopenic patients, 1083

**New Periodicals,** 110, 252, 846, 1119, 1428, 1598

**News,** 122, 258, 408, 563, 706, 852, 992, 1128, 1272, 1435, 1612, 1728

Additional evidence published in support of changing i.v. administration sets every 48 hours rather than every 24 hours, 1612

American Association of Colleges of Pharmacy members meet with congressional aides, 1133

American Medical Association panel issues guidelines on parenteral use of essential trace elements, 993

American Pharmaceutical Association Remington Medal awarded to Eugene White, 564

American Society of Consultant Pharmacists-Lilly publish results of survey on long-term care pharmacy operations, 1132

American Society of Consultant Pharmacists surveys unit dose reimbursement policies of Medicaid programs, 1442

American Society of Hospital Pharmacists and the American Hospital Association develop patient education workshops, manuals, 564

Appointments and promotions, 124, 263, 416, 569, 710, 859, 998, 1133, 1278, 1444, 1613, 1731

Archambault, George F., 861; Arrington, David M., 1613; Baumgartner, R. Paul Jr., 128; Bell, J. Edward, 1133; Bingham, Johnnie Jr., 1613; Blackburn, Daryl, 1731; Bratland, Gary L., 1614; Bryant, Stephen H., 859; Burke, W. Arthur, 1613; Cardi, Vincent, 1731; Chaikin, Philip, 710; Chapman, Jeff, 710; Ciullo, Steven J., 416; Colangelo, Anthony, 1133; Crimson, Miles L., 1731; Croft, Al, 416; Culkin, Thomas T., 263; Cupit, Gary C., 998; Dahlin, Patricia A., 1278; Davern, Paul, 569; De-

Leon, Richard F., 998; DelVecchio, Gilda Jo, 710; Di-Bona, John R., 1613; DiMatta, Philip, 1613; Doutre, William H., 1133; Duncan, Edgar, 1444; Edgerton, Walter L., 416; Faris, Philip W. Jr., 1731; Feldman, Marvin J., 569; Fink, Joseph L. III, 1613; Finkelstein, Burt, 1613; Fishman, Doris A., 1613; Flesh, Judy S., 1731; Gerraughty, Robert J., 1613; Gever, Larry N., 1278; Gibson, Ernest L., 416; Glorioso, John A. Jr., 263; Goldstein, Eric, 1731; Grady, Lee T. (Tim), 416; Greene, Ronald, 1731; Grimm, Robert L., 569; Haley, Nancy Jane, 1444; Hamet, Harry, 1613; Hamilton, Stephen F., 1731; Hansen, Carolee, 1731; Harris, William, 1731; Hopefl, Alan W., 1613; Hurlow, George D., 1444; Jewett, Christina, 859; Jozefczyk, Arthur D., 1444; Juhl, Randy P., 1731; Kaul, Alan, 1613; Kleinberg, Michael L., 1444; Klepcyk, James C., 1444; Koehler, Jim, 1133; Kubica, Anthony J., 1278; Lancaster, William J., 1613; Leavitt, Linwood S., 1282; Lerario, Donald, 1278; Lima, John, 569; Loeb, Allan J., 1613; Lopez, Larry M., 1731; Lowenthal, Werner, 128; Mannone, Louis J., 1444; Marquardt, Karl W., 861; Marsh, David A., 416; McAllister, James, 1731; Meana, Berry J., 1613; Meyers, John C., 1278; Mirando, Richard, 1731; Moore, Timothy D., 128; Morris, Stuart N., 859; Mussie, Mark, 1731; O'Brien, William E., 1282; Olesen, Marrakay, 1731; Paiva, Kenneth B., 861; Paulson, Patrick T., 710; Pearson, Warren, 1613; Pelletier, Mark, 1731; Pevonka, M. Peter, 1613; Pollhammer, Richard W., 1614; Pope, Patricia Ann, 263; Powell, Stephen, 1613; Propst, Edward H., 859; Roehrl, Pamela, 263; Rosse, Bruce D., 128; Rosenthal, Alan, 1444; Rudd, Christine, 1731; Russell, Wayne, 1731; Ryan, Patrick B., 124; Saito, Thomas E., 124; Schmadel, Linda, 710; Schneider, Philip J., 128; Scratower, Renee R., 1614; Silkey, Werner G., 124; Spears, Jeffrey B., 1133; Steckel, Steven D., 1613; Summerfield, Marc R., 416; Tanazewski, Alexander, 998; Tanner, David J., 859; Traub, Scott L., 416; Trudeau, Terry, 264, 998; Turk, James B., 859; Vinson, Michael C., 128; Vitale, Paul J., 1613; Wainwright, C. Francis, 859; Weisz, Elvira, 264; Williams, Ronald D., 416; Zook, Susan, 859  
AV program available on plastic bag system preparation of TPN solutions, 263  
The business of health, 408  
Capitation, technicians and specialty certification issues acted on by AACP House, 1435  
Certain British hospitals reduce the number of antibiotics used and report cost savings, 1129  
Checklist helps patients keep track of their medications, 996  
College-based technician training programs: Producing without planning?, 992  
Columbia University recognized as comprehensive cancer center, 708  
Congressman Rogers recognized for health service by AACP, 124  
Detailing policies in hospitals surveyed, 1129  
Device reporting program expanded to hospitals, 1444  
Estrogen prescribing practices scrutinized at NIH conference, 1728  
FDA gives nonprescription status to five drug ingredients, 565  
FDA objectives for 96th Congress outlined by general counsel, 854  
Feasibility of reopening southwest thyroid cancer study assessed, 566  
Federal funding extended for study of patient education programs, 1613  
Food safety regulation panel urges Congress to revamp regulatory statutes, 706  
Group purchasing of pharmaceuticals cuts millions from health care costs, 1128  
Grover Bowles receives APhA Hugo H. Schaefer Award, 564  
Guidelines for selection, processing and use of LVP containers and closures approved, 1132  
Health care fellowships available through Hospital Research and Educational Trust, 1276  
HEW report addresses health, promotion and disease prevention, 1435  
Hospital formularies: How selective are they? 563  
International Congress of Pharmaceutical Sciences to meet in September, 706  
Investigational drug protocols made available to hospital pharmacists by Merck Sharp & Dohme, 416  
The life of a pharmacist (who happens to be a Vietnamese refugee), 1272  
Lilly develops educational program on Dobutrex for pharmacists, 996  
Lilly surveys for trends in hospital pharmacy, 1282  
Mandatory patient counseling regulations have little effect on hospital pharmacists, 410  
Medical charts shown to be deficient in recording outpatient drug therapy, 706  
Medication awareness program available from APhA, 996  
Meetings and continuing education programs, 128, 264, 416, 569, 710, 861, 998, 1133, 1282, 1444, 1732  
Model for hypertension services developed by New York students, 998

More unit dose products are forecast, 1728  
National Association of Boards of Pharmacy approves recommendations on patient product information, information transfer, institutional pharmacy inspection form, 1444  
New Clinical Science Center opens at University of Wisconsin, 708  
New Medical University of South Carolina will prepare students for industrial pharmacy, 856  
New monographs, title changes and revisions in fifth USP-NF supplement, 414  
New *Voluntary Effort Chartbook* reviews health care, hospital cost issues, 1132  
News briefs, 128, 264, 418, 570, 710, 862, 1000, 1134, 1284, 1445, 1614, 1733  
American Foundation for Pharmaceutical Education, 570; Anderson, Janice D., 570; Anderson, Joanne, 1134; *Applied Therapeutics for Clinical Pharmacists*, 1734; Auger, Robert R., 418; Bair, Jan N., 1614; Barger, Robert C., 1614; Beckerman, Joseph H., 862; Bellinger, Robert E., 264; Bergen, John V., 1734; Bjerke, Paul G., 418; Boots Pharmaceuticals, Inc., 710; *Breast Cancer Digest*, 1446; Bryant, Albert, 862; Byrum, Woodrow R., 714; Cady, Thomas E., 1446; College of Pharmacy, University of Illinois at the Medical Center, 710; *Cumulative Index of Hospital Literature*, 1975-1977, 714; Demicki, Eugene L., 128; Elenbaas, Robert M., 128; Fleming, Marjorie L., 128; Florey, Klaus G., 264; Freedman, George I., 1614; Goyette, Gordon F. Jr., 1614; Granat, Alan L., 714; Harding, Roland F., 1000; Harmon, Roger, 1134; Home parenteral nutrition, 1134; Hospital cost containment through operations management, 1445; Icaza, Luis A., 862; Institute for Brain Function Research, 1446; Ivers-Lee, 1446; Johnson, Bentley N., 1445; Kansas Council of Hospital Pharmacists, 1000; Keasler, Gunther Karl, 1134; Kleinman, Larry M., 1134; Latola, Clifton J., 1284; Levy, Gerhard, 1134; Lifemark Corporation, 1446; Eli Lilly and Company, 1000; Macy, S. A., 1445; Manufacturer disclosure, 79, 1445; Massey, Beverly Kay, 862; McKesson Drug Company, 1734; McLaugherty, Larry, 1134; Medic Alert Foundation International, 1133; Medical Information Ltd., 1445; Mehl, Barnard, 1000; Michigan Department of Mental Health, 570; Miller, Jacob W., 1734; National Conference on High Blood Pressure Control, 1445; National Eye Institute, 418; Neutron Products, Inc., 1445; O'Brien, William P., 418; Orange County (California) Society of Hospital Pharmacists, 1445; Pharmacy technician training program, 1284; Pharmacy school admission requirements, 264; Rohay, Juan R., 1445; San Fernando-Ventura Society of Hospital Pharmacists, 1133; Sandusky, Ray, 1614; *Scientific Bases for Identifying Potential Carcinogens and Estimating Their Risk*, 714; Sewell, Winifred, 1134; Shaw, Donna M., 1614; Skolaut, Milton W., 1133; Soltot, Art, 714; Sonnedecker, Glenn A., 418; Sorby, Donald L., 128; South Dakota Society of Hospital Pharmacists, 418; Sramek, John J., 714; State board of newsletter project, 1446; Stetler, C. Joseph, 1134; Stewart, Nathaniel, 1446; Stinebaugh, Ernest H., 1734; Swartz, Allan J., 1734; Tanja, Jon J., 128, 862; Thomas Jefferson University Hospital, 1446; Timberlake, Claude V., 1733; Tornatore, Frank L., 714; "Traditional Japanese Medicine and Its Graphics", 570; Trissel, Lawrence A., 1134; University of California at San Francisco School of Pharmacy, 1734; University of Connecticut, 714; Wells, Patrick R., 570; Zeisler, John, 862; Zenk, Karin, 1445; Zoloth, Art, 714; Zupko, Arthur G., 1000, 1134  
Nominations open for service area experts on USP Committee of Revision, 854  
North Carolina task force recommends expanded role for pharmacist, 123  
Nursing Practice Advisory Panel formed to review USP publication, 710  
156 name changes for 1980 USP XX-NF XV, 1438  
Pan-Pacific conference is stop on ASHP tour, 1730  
Pharmacist prescribing being pursued in state legislatures, 258  
Physicians found to be unaware of hospital charges for drugs and services, 1612  
Program for cost-saving i.v. antibiotic therapy at home reported, 993  
Report reviews status of pharmacy: projects surplus by mid-1980s, 261  
Scientists review status of pertussis vaccine, 124  
Shared hospital services increase, 1730  
Standards of pharmacy practice published by AACP and APhA, 854  
Study questions necessity of daily change of infusion administration sets, 1129  
Study reveals overuse of antibiotics for prophylaxis, 1612  
Study shows drug product selection seldom used in Florida, 565  
Study shows physicians underestimate cost of health services, 856  
Survey of families reveals lack of coherent health philosophy, 1440  
*The Swine Flu Affair:* Good reading and preventive

medicine for future decision-making, 563  
 Thumbs down on federal regulation of hospital costs—views of five former assistant secretaries for health, 852;  
 Unit dose at the VA caught in bureaucratic snarl, 122  
 Updated report on the dialysis and hemoperfusion of poisons and drugs available, 566  
 USP and FDA establish antibiotic monograph subcommittee, 1444  
 Wisconsin law allows optometrists to use diagnostic drugs, 859  
 Women pharmacists needed for vocational interest study, 414  
**Nitrofurantoin**  
 information; comparison, services, 1215  
 therapy; review, 342  
**Nitroglycerin**; injections; i.v. extemporaneous, stability, 173  
**Norethindrone**; combination, mestranol; ischemic bowel disease, patient, 1103  
**Nurses**  
 assistants; pharmacy, students, internships, emphasis on nursing assistant and medication administration through nursing service, 791  
 education; continuing, one-day program, by pharmacists, 44  
 injections, workload; i.v., comparison systems, preparation, 1497  
 role; pharmaceutical services, decentralized, without satellites, 1513  
 warfarin; education, patients, hospitals, 219  
**Nystatin**; mechanism of action; toxicity, dosage availability and costs, review, 1326

**O**

**Osmolarity**; solutions; i.v. and parenteral nutrition methods, 1357  
**Oxacillin**; toxicity; skin, patients, 609  
**Oxolinic acid**; mechanism of action; pharmacokinetics, dosage, adverse reactions, review, 1077  
**Oxycodone**; combination, acetaminophen; therapy, symptoms, folic acid allergies, patient, 1565  
**Oxyphenbutazone**  
 gout; and hyperuricemia, therapy, discussion, 497  
 sarcoidosis; therapy, discussion, 351

**P**

**Package inserts**; patients; Drug Regulation Reform Act of 1979, provisions, Kennedy bill, 1230; regulations, FDA, pharmacist's responsibility, 226  
**Packaging**  
 amoxicillin trihydrate; unit dose, reconstituted, temperature, effects on stability, 209  
 ampicillin; unit dose, reconstituted, temperature, effects on stability, 209  
 nitroglycerin; injections, i.v., hospital pharmacy, 173  
 penicillin V potassium; unit dose, reconstituted, temperature, effects on stability, 209  
 unit dose; syringes, oral, plastic, various temperatures, effects on penicillin V potassium stability, 205  
**Paget's disease**; calcitonin; self-medication, costs, effects, clinical pharmacists training programs, inpatients, 1527  
**Papaverine hydrochloride**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Parasympatholytic agents**; propantheline bromide; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Parenteral nutrition**  
 additives; stability, and incompatibilities, FreAmine II, 511  
 adverse reactions; solutions, fat-free, patient, 230  
 amino acids; concentration, formulary change, hospitals, 57  
 policies and procedures; manuals, development, review, 517  
 programs; pharmacists, hospital, role, 648  
 self-medication; costs, effects, clinical pharmacists training programs, inpatients, 1527  
 solutions; osmolarity, methods, 1357  
 soybean oil; therapy, patients with fatty-acid deficiencies, 230  
 therapy; pharmacists, role, patient outcome and costs, 785  
**Parenterals**, see **Injections**  
**Particles**  
 amphotericin B; stability, in FreAmine II, 511  
 ampicillin sodium; stability, in FreAmine II, 511  
 contamination; cefazolin sodium, injections, in sodium chloride and dextrose in water, 657  
 FreAmine II; stability, with additives, 511  
**Patient information**  
 consultation; clinical pharmacists, family-practice office,

912; parenteral nutrition, pharmacists, hospital, role, 648; pharmacists, role, clinics, screening and prescribing, ambulatory patients, 916; toxicity, skin, monitoring, hospitals, patients, 609  
**Deferoxamine**; pharmacists, hospital, consultation, Cooley's anemia patients, 788  
**Diabetes mellitus**; clinical pharmacists, role, management, 1321  
**Hypertension**; clinical pharmacists, role, management, 1321  
 medical histories; anticoagulants, pharmacists, hospital, role, ambulatory clinic, 645  
**Package inserts**; Drug Regulation Reform Act of 1979, provisions, Kennedy bill, 1230; regulations, FDA, pharmacist's responsibility, 226  
**Profile**; development, from drug-charge records, hospitals, 1347; outpatients, survey, 1978, university-affiliated hospitals, 1193; pharmaceutical services, decentralized, without satellites, 1513  
**Self-medication**; clinical pharmacists, role, cost savings, inpatients, 1527  
 warfarin; hospitals, pharmacists and nurses, 219  
**Patients**  
 ambulatory; anticoagulants, clinic, pharmacists' role, 645; clinic, pharmacists, role, screening and prescribing, 916  
 education; adrenalectomy, by hospital pharmacists, 1212; theophylline, audiovisual, with and without pharmacists present, 63; warfarin, hospitals, pharmacists and nurses, 219  
 health care; quality, effects, clinical pharmacy services, 325  
 inpatients; length of stay, effects, drug distribution systems, drug administration and clinical pharmacy services, 1691  
 outpatients; hospital pharmacy, planning and design, facilities, modernization, 371; interactions, monitoring, 653; pharmaceutical services, survey, 1978, university-affiliated hospitals, 1193  
**Pectin**  
 combination, kaolin; comparison, charcoal activated, effects, aspirin absorption, patients, 1097  
 diarrhea; therapy, discussion, 757  
**Pediatrics**; poisoning; pharmacists, consultation, clinical toxicology service, 1087  
**Penicillin G**; toxicity; skin, patients, 609  
**Penicillin G potassium**; hyperpyrexia; therapy, thiordiazine-induced, schizophrenic patient, 674  
**Penicillin V potassium**; stability; syringes, oral, plastic, various temperatures, 205  
 temperature, freezing, effects, reconstituted unit dose, 209  
**Pentaerythritol tetranitrate**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539  
**Pentazocine lactate**; incompatibilities, glycopyrrolate, effects, pH, 508  
**Pentothenic acid sodium**; incompatibilities; glycopyrrolate, effects, pH, 508  
**Personnel**; admixtures; injections, education, control, quality, 606  
**Personnel, pharmacy**  
 disaster planning; role, 1337  
 evaluations; methods, 187  
 hospitals; performance, appraisal, methods, 1876  
 supportive; technicians, decentralized services without satellites, 1513; technicians, training programs, 1533; technicians, workload, i.v. injections, comparison, systems, 1497; workload, comparison, two methods, 59  
**Pharmaceutical education**, see **Education, pharmaceutical**  
**Pharmaceutical services**  
 decentralized; hospitals, without satellites, 1513; operating room, establishment, 1342  
 hospitals; effects, adverse reactions, length of stay, inpatients, 1691; 1978, comparison, 1975, survey, 316; pricing, computerized system using a markup and a dose fee, 360; professional fees, based upon medication administration record, 365; strategy, increased demand, 1553  
 professional fees; hospitals, based upon drug cost plus per-diem fees, 355; hospitals, pricing, based upon per-diem drug costs, 363  
**Pharmacists**  
 Harvey A. K. Whitney Lecture Award; 1978, patient, 311  
 package inserts; regulations, FDA, 226  
 parenteral nutrition; therapy, role, patient outcome and costs, 785  
 reimbursement; clinical pharmacy, services, models, 1548; costs, savings, inpatients, self-medication programs, 1527; education, adrenalectomy patients, 1212; third-party, dosage schedules, pharmacokinetics, 1523  
 role; clinics, screening and prescribing, ambulatory patients, 916; nurses, continuing education, one-day program, 44  
**Pharmacists, hospital**  
 anticoagulants; role, clinic, ambulatory, development, operation, patient management protocols and education, 645  
 consultation; deferoxamine, self-medication, patients, 788; poisoning, pediatrics, clinical toxicology service, 1087  
 disaster planning; role, 1337  
 drug use review; heparin sodium and warfarin sodium, embolism, thrombosis and thromboembolism, 214  
 education; continuing, decentralized staff program, 50; patients, adrenalectomy, 1212; patients, effects, audiovisual aids for theophylline information, 63  
 Great Britain; history, 492  
 parenteral nutrition; programs, role, 648  
 performance appraisal, methods, 1676  
 role; aminoglycosides, blood levels, rational therapy, 1080; pharmaceutical services, decentralized, without satellites, 1513  
 toxicity; skin, monitoring, patients, 609  
 warfarin; education, patients, hospitals, 219  
 workload; comparison, two methods, 59; computers, word-processing machines compared, 1529; time studies, productivity evaluation, 201  
**Pharmacokinetics**  
 bretylium tosylate; review, 1189  
 butorphanol tartrate; review, 1683  
 cefamandole nafate; review, 1503  
 cefotixin sodium; review, 1503  
 dosage schedules; clinical pharmacists, development and reimbursement, 1523  
 diphosphonate; patients, 1179  
 erythromycin; and derivatives, review, 1185  
 gentamicin; ascitic patients, 1704  
 heparin; dosage schedules, effects, costs, tests and errors, 920  
 hypotensive agents; dosage schedules, discussion, 1222; dosage schedules, patient individualization, methodology, 802  
 lidocaine hydrochloride; withdrawal, myocardial infarction patients, 778  
 methenamine hippurate; review, 1509  
 methenamine mandelate; review, 1509  
 models; heparin, methodology, injection rate, 782  
 nalidixic acid; review, 1071  
 oxolinic acid; review, 1077  
 services; costs, hospitals, 368  
 sulfamethoxazole, combination, trimethoprim; review, 893  
 trimethoprim, combination, sulfamethoxazole; review, 893  
**Pharmacokinetics in Drug Therapy**, 802, 1222  
**Pharmacology**; nitrofurantoin; review, 342  
**Pharmacy**  
 clinical, see **Clinical pharmacy**  
 education, see **Education, pharmaceutical**  
 laws; inspections, warrantless, discussion, 85  
 personnel, see **Personnel, pharmacy**  
 students; internships, emphasis on nursing assistant and medication administration through nursing service, 791  
**Pharmacy, institutional**; patients; ambulatory, clinic, pharmacists, role, screening and prescribing, 916  
**Pharmacy, institutional, hospital**  
 admixtures; injections, containers, plastic, dextrose in water, compounding times and contamination rates, 513  
 amino acids; concentration, parenteral nutrition solutions, formulary change, 57  
 cefazolin; prescribing, control, programs, 1055  
 charges; drugs, based upon medication administration record, 365  
 computers; comparison, word-processing machines, 1529; files, multifunctional drug, development, 1197  
 costs; pharmacokinetics, services, 368  
 decentralized; emergency room, costs, 52  
 disaster planning; personnel, role, 1337  
 drug information; services, effects, clinical pharmacy, 1520  
 drug inventory, storage and stability, use of lot numbers, 1545  
 education; American Society of Hospital Pharmacists, topics, 1967-1978, Midyear Clinical Meeting papers, 1372  
 education; pharmaceutical; residencies, screening and selection procedure, 194  
 injections; i.v., equipment, comparison, systems, contamination, costs and workload, 1497  
 outpatients; services, survey, 1978, university-affiliated, 1193  
 personnel; evaluations, methods, 178  
 pharmaceutical services; 1978, comparison, 1975, survey, 316; pricing, per-diem system, 363  
 planning and design; outpatients, ambulatory, facilities, modernization, 371  
 policies and procedures; manuals, admixture services, parenteral nutrition, development, review, 517  
 reimbursement; education, adrenalectomy patients, 1212  
 services; decentralized, operating room, and recovery room, establishment, 1342; decentralized, without satellites, 1513

statistics; purchasing, and inventory, 1978 survey, 650  
workload; pharmacists, and supportive personnel, comparison, methods, 59

**Phenobarbital:** tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539

**Phenobarbital sodium:** hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674

**Phenothiazines:** analgesics and antipyretics; rational therapy, review, 633

**Phenylobutazone:** gout; and hyperuricemia, therapy, discussion, 497

**Phenytoin:** information; comparison, services, 1215  
toxicity; skin, patients, 609

**Phenytoin sodium:** antidotes; poisoning, digitoxin, patients, 92

capsules; stability, storage, counting machine, spectrometry and colorimetry, 1539

hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674

**Physicians:** information; effects, clinical pharmacist consultation, family-practice office, 912

prescribing; albumin, drug use review, hospitals, 1205; cefazolin, control, programs, hospital, 1055; effects, clinical pharmaceutical services, hospitals, 1553; effects, length of hospital stay, pyelonephritis patients, 1334; rational therapy, discussion, 1099

**Planning and design:** hospital pharmacy; outpatients, ambulatory facilities, modernization, 371

**Plastics:** catheters; toxicity, thrombosis, patients, effects, physical characteristics, 1707

containers; admixtures, injection, dextrose in water, compounding times and contamination rates, 513; effects, stability, extemporaneous nitroglycerin i.v. injections, 173

incompatibilities; diazepam, i.v., in dextrose, sodium chloride, Ringer's injection and Ringer's injection lactated, 505

syringes; penicillin V potassium, oral, stability, 205

**Pneumococcal vaccines:** review, 773

**Poisoning:** digitoxin; antidotes, patients, 92

drugs; antidotes, effects, electrolyte blood levels, patients, 1366

pediatrics; pharmacists, consultation, clinical toxicology service, 1087

**Polarography:** ions; stannous, stability, comparison, commercial and extemporaneous radiopharmaceutical kits, 1370

**Polyvinyl chloride:** containers; effects, insulin, availability, low-dose continuous injections, 330

**Pore size:** filters; membrane, inline, final, effects, survival, following injections of contaminated i.v. fluids, rabbits, 1711

**Potassium chloride:** antidotes; poisoning, digitoxin, patients, 92

solutions, osmolarity, methods, 1357

**Potassium iodide:** toxicity; skin, patients, 609

**Precipitates:** FreAmine II, injections, additive stability, 511

**Presnisolone acetate:** solutions, ophthalmic; poly-

chondritis, relapsing, therapy, patients, 806

**Prednisone:** polychondritis, relapsing; therapy, patient, 806

purpura; thrombotic thromboembolic, therapy, patient, 89

**Prescriptions:** antibiotics; prescribing, effects, length of hospital stay, pyelonephritis patients, 1334

anti-infective agents; prescribing, effects, length of hospital stay, pyelonephritis patients, 1334

cefazolin; prescribing, control, programs, hospital, 1055

costs; emergency room, decentralized pharmacy service, 52

drug use review; hypotensive agents, comparison, methods, family-practice clinic, 1665

pricing; outpatients, 1978 survey, university-affiliated hospitals, 1193

**Preservatives:** benzoin acid; effects, adulteration tests on meperidine hydrochloride, 1094

m-cresol; effects, adulteration tests on meperidine hydrochloride, 1094

sodium acetate; solutions, protein hydrolysates and dextrose, 1672

**Probenecid:** gout; and hyperuricemia, therapy, discussion, 497

**Professional fees:** pharmaceutical services; hospitals, based upon drug cost plus per-diem fees, 355; hospitals, based upon medication administration record, 365; hospitals, computerized system using a markup and a dose fee, 360; hospitals, pricing, based upon per-diem drug costs, 363

**Promethazine hydrochloride:** hyperpyrexia; therapy, thioridazine-induced, schizophrenic patient, 674

**Propantheline:** diarrhea; therapy, discussion, 757

**Propantheline bromide:** tablets; stability, storage, counting machine spectrometry and colorimetry, 1539

**Propranolol hydrochloride:** tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539

**Protein hydrolysates:** and dextrose; solutions, sodium acetate, preservatives, 1672

**Psychotherapeutic agents:** lithium carbonate; information, comparison, services, 1215

toxicity; extrapyramidal disorders, prophylaxis, anti-parkinson agents, patients, 641

**Purchasing:** drugs; hospital pharmacy, computers, use, 1197; hospitals, survey, 1978; comparison, 1975, 316; hospitals, U.S., General Accounting Office report, 1171

hospital pharmacy; statistics, 1978 survey, 650

**Purpura:** dipryidamole; thrombotic thromboembolic, therapy, patient, 89

prednisone; thrombotic thromboembolic, therapy, patient, 89

## Regulations

effects; rational therapy, discussion, 1099  
package inserts; patients, FDA, pharmacist's responsibility, 226

**Reprints:** articles; journals, requests, response rates, 1219

**Rescinamine:** drug interactions; monitoring, Medicaid patients, 923

**Reserpine:** drug interactions; monitoring, Medicaid patients, 923

**Reye's syndrome:** drugs; therapy, review, 767

**Ringer's injection:** additives; injections, plastics, 505

**Ringer's injection lactated:** additives; injections, diazepam, i.v., incompatibilities, plastics, 505

effects; insulin availability, low-dose continuous injections, 330

incompatibilities; glycopyrrolate, effects, pH, 508

## S

**Salaries:** personnel, pharmacy; supportive, injections, i.v., comparison, systems, preparation, 1497

**Saliva levels:** dyphylline; patients, 1179

**Sarcoidosis:**

allopurinol; therapy, discussion, 351

chloroquine; therapy, discussion, 351

levamisole hydrochloride; therapy, discussion, 351

methotrexate; therapy, discussion, 351

oxyphenbutazone; therapy, discussion, 351

steroids cortico-; therapy, discussion, 351

**Secobarbital sodium:** incompatibilities; glycopyrrolate, effects, pH, 508

**Security:** hospital pharmacy; effects, decentralized operating room pharmacy services, 1342

**Sedatives and hypnotics:** phenobarbital; tablets, stability, storage, counting machine, spectrometry, and colorimetry, 1539

**Simethicone:** combination, aluminum hydroxide, magnesium hydroxide; tablets, equivalency, generic, acid reactivity, in vitro, 660

**Sodium acetate:** preservatives; solutions, protein hydrolysates and dextrose, 1672

**Sodium bicarbonate:**

buffers; cardioplegic solutions, effects, stability, 1361

incompatibilities; glycopyrrolate, effects, pH, 508

**Sodium carbonate:** buffers; cardioplegic solutions, effects, stability, 1361

**Sodium chloride:**

additives; cefazolin sodium, effects, membrane filters, on concentration and particle contamination, 657; injections, diazepam, i.v., incompatibilities, plastics, 505

adulteration; meperidine hydrochloride, dosage forms, 1094

alone and with dextrose; solutions, effects, insulin availability, low-dose continuous injections, 330

diuretics; effects, stability, extemporaneous nitroglycerin i.v. injections, 173

heparin sodium; stability, 618

solutions; osmolarity, methods, 1357

**Sodium salicylate:** adsorption; charcoal activated, reduced by sucrose, in vitro, 797

**Solutions:**

cisplatin; stability, UV spectrometry, 38

dextrose; preservatives, sodium acetate, 1672

heparin; use, cytopathology, bottles, collection of body cavity fluids, 211

protein hydrolysates and dextrose; preservatives, sodium acetate, 1672

**Solutions, ophthalmic:**

homatropine hydrobromide; polychondritis, relapsing, therapy, patient, 806

prednisolone acetate; polychondritis, relapsing, therapy, patient, 806

**Soybean oil:** parenteral nutrition; therapy, patients with fatty-acid deficiencies, 230

**Spasmolytics:**

aminophylline; absorption, excretion, blood levels, lack, effects, aluminum hydroxide, combination, magnesium hydroxide patients, 1059

dyphylline; pharmacokinetics, patients, 1179

papaverine hydrochloride; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539

theophylline; information, comparison, services, 1215;

tablets, sustained-action, dosage forms, blood levels, asthmatic children, 1698

**Spectrometry:** dosage forms; tablets, and capsules, storage, counting machine, effects on stability, 1539

**Spectrometry, ultraviolet:**

cisplatin; solutions, stability, 38

meperidine hydrochloride; dosage forms, adulteration, 1094

penicillin V potassium; stability, syringes, oral, plastic, various temperatures, 205

- Spironolactone** availability; effects, neomycin sulfate, patients, 1701 tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539
- Stability** additives and FreAmine II; discoloration, and precipitation, 511 amoxicillin trihydrate; temperature, freezing, effects, reconstituted unit dose, 209 amphotericin B; additives, FreAmine II, incompatibilities, 511 ampicillin; temperature, freezing, effects, reconstituted unit dose, 209 ampicillin sodium and FreAmine II; particles, 511 antibiotics; injections, FreAmine II, incompatibilities, 511 aspirin; tablets, storage, counting machine, spectrometry and colorimetry, 1539 cefazolin sodium; injections, effects, membrane filters, on concentration and particle contamination, in sodium chloride and dextrose in water, 657 cefoxitin sodium; additives, injections, i.v., 33 charcoal activated; adsorption, lack, sucrose, in vitro, 797 chlorpheniramine maleate; tablets, storage, counting machine, spectrometry and colorimetry, 1539 cisplatin; solutions, UV spectrometry, 38 diazepam; injections, i.v., in plastic and glass, 505; tablets, storage, counting machine, spectrometry and colorimetry, 1539 doxorubicin hydrochloride; injections, effects, temperature, 1536 drugs; hospital pharmacy, use of lot numbers, 1545; temperature, lists, not to be refrigerated, 1541 FreAmine II and additives, discoloration, and precipitation, 511 glycopyrrolate; incompatibilities, additives, effects, pH, 508; incompatibilities, i.v., vehicles and additives, 508 heparin sodium; additives, injections, pH and time, in dextrose in water and dextrose in sodium chloride, 618 hydralazine hydrochloride; tablets, storage, counting machine, spectrometry, and colorimetry, 1539 methylldopa; tablets, storage, counting machine, spectrometry and colorimetry, 1539 nitroglycerin; injections, i.v., extemporaneous, 173 papaverine hydrochloride; tablets, storage, counting machine, spectrometry and colorimetry, 1539 penicillin V potassium; syringes, oral, plastic, various temperatures, 205; temperature, freezing, effects, reconstituted unit dose, 209 pentaerythritol tetrahydrate; tablets, storage, counting machine, spectrometry and colorimetry, 1539 phenobarbital; tablets, storage, counting machine, spectrometry and colorimetry, 1539 phenytoin sodium; capsules, storage, counting machine, spectrometry and colorimetry, 1539 propantheline bromide; tablets, counting machine, spectrometry and colorimetry, 1539 propranolol hydrochloride; tablets, storage, counting machine, spectrometry and colorimetry, 1539 sodium salicylate; adsorption, sucrose and activated charcoal mixtures, 797 spironolactone; tablets, storage, counting machine, spectrometry and colorimetry, 1539 stannous chloride dihydrate; ions, stannous, comparison, commercial and extemporaneous radiopharmaceutical kits, 1370 sulfisoxazole; tablets, storage, counting machine, spectrometry and colorimetry, 1539 tetracycline; additives, FreAmine II, incompatibilities, 511 tolbutamide; tablets, storage, counting machine, spectrometry and colorimetry, 1539 **Stannous chloride dihydrate**; stability; ions, stannous, comparison, commercial and extemporaneous radiopharmaceutical kits, 1370
- Statistics** hospital pharmacy; purchasing, and inventory, 1978 survey, 650 pharmaceutical services; hospitals, 1978, comparison, survey, 1975; 316
- Sterility** admixtures, injections, compounding times and contamination rates, 513
- Steroids, cortico-** education; patients, adrenalectomy, by hospital pharmacists, 1212
- Reye's syndrome; therapy, review, 767 sarcoidosis; therapy, discussion, 351
- Storage** amoxicillin trihydrate; temperature, freezing, effects, stability, reconstituted unit dose, 209 ampicillin; temperature, freezing, effects, stability, reconstituted unit dose, 209 diazepam; containers, plastic, decreased stability, 505 dosage forms; tablets, and capsules, counting machine, effects on stability, spectrometry and colorimetry, 1539 drugs; hospital pharmacy, use of lot numbers, 1545 heparin sodium; additives, stability, in dextrose in water and dextrose in sodium chloride, 618 nitroglycerin; injections, i.v., extemporaneous, stability and potency, 173 penicillin V potassium; temperature, freezing, effects, stability, reconstituted unit dose, 209 stannous chloride dihydrate; ions, stannous, stability, comparison, commercial and extemporaneous radiopharmaceutical kits, 1370
- Sucrose**; adsorption; charcoal activated, lack, in vitro, 797
- Sulfamethoxazole**; combination, trimethoprim; effects, mechanism of action, pharmacokinetics, drug interactions and adverse reactions, review, 893; infections, combined therapy, granulocytic cancer patients, 178
- Sulfapyridine**; gout; and hyperuricemia, therapy, discussion, 497
- Sulfisoxazole**; tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539
- Surgical supplies**; administration sets; contamination, microbiological, determination, membrane filter set, 1202; effects, insulin availability, low-dose continuous injections, 330; filters, membrane, inline, effects, air flow, 749; models, flow rates, 338
- Sustained-action medications**; theophylline; tablets, comparison, regular aminophylline tablets, effects and blood levels, patients, 613; tablets, dosage schedules, blood levels, asthmatic children, 1698
- Sympatholytic agents**; tolazoline; rational therapy, clonidine overdose, review, 906
- Syringes** meperidine hydrochloride; dosage forms, adulteration, visual, colorimetry and UV spectrometry, 1094 plastic; penicillin V potassium, oral, stability, 205
- Syrups**; meperidine hydrochloride; dosage forms, adulteration, visual, colorimetry and UV spectrometry, 1094
- T
- Tablets** aluminum hydroxide, combination, magnesium hydroxide, simethicone; equivalency, generic, acid reactivity, in vitro, 660 aminophylline; comparison, theophylline sustained-action tablets, effects and blood levels, patients, 613 ascorbic acid; stability, storage, counting machine, spectrometry and colorimetry, 1539 aspirin; stability, storage, counting machine, spectrometry and colorimetry, 1539 chlorpheniramine maleate; stability, storage, counting machine, spectrometry, and colorimetry, 1539 diazepam; stability, storage, counting machine, spectrometry and colorimetry, 1539 hydralazine hydrochloride; stability, storage, counting machine, spectrometry and colorimetry, 1539 magnesium hydroxide, combination, aluminum hydroxide, simethicone; equivalency, generic, acid reactivity, in vitro, 660 methylldopa; stability, storage, counting machine, spectrometry and colorimetry, 1539 papaverine hydrochloride; stability, storage, counting machine, spectrometry and colorimetry, 1539 pentaerythritol tetrahydrate; stability, storage, counting machine, spectrometry and colorimetry, 1539 phenobarbital; stability, storage, counting machine, spectrometry and colorimetry, 1539 propantheline bromide; stability, storage, counting machine, spectrometry and colorimetry, 1539 propranolol hydrochloride; stability, storage, counting machine, spectrometry and colorimetry, 1539 simethicone, combination, aluminum hydroxide, magnesium hydroxide; equivalency, generic, acid reactivity, in vitro, 660 spironolactone; stability, storage, counting machine, spectrometry and colorimetry, 1539 sulfisoxazole hydrochloride; stability, storage, counting machine, spectrometry and colorimetry, 1539 theophylline; sustained-action, comparison, regular aminophylline tablets, effects and blood levels, patients, 613; sustained-action, dosage schedules, blood levels, asthmatic children, 1698 tolbutamide; stability, storage, counting machine, spectrometry and colorimetry, 1539
- Temperature** amoxicillin trihydrate; effects, freezing, on stability, reconstituted unit dose, 209 ampicillin; effects, freezing, on stability, reconstituted unit dose, 209 cefoxitin sodium; stability, additives, 33 cisplatin; stability, solutions, 38 doxorubicin hydrochloride; injections, stability, effects, 1536
- drugs; stability, lists, not to be refrigerated, 1541 ions; stannous, stability, stannous chloride dihydrate, comparison, commercial and extemporaneous ions, radiopharmaceutical kits, 1370 nitroglycerin; injections, i.v., extemporaneous, effects on stability, 173 penicillin V potassium; effects, freezing, on stability, reconstituted unit dose, 209; stability, syringes, oral, plastic, 205
- Tests**; sterility; admixtures, injections, contamination, 1493
- Tests, laboratory**; thromboplastin time; effects, heparin, dosage schedules, based upon pharmacokinetics, 920
- Tetracycline**; interactions; antacids, monitoring, programs, outpatients, 653
- Tetracycline hydrochloride**; incompatibilities; FreAmine II, visual, 511
- Theophylline** blood levels; lack, effects, aluminum hydroxide, combination, magnesium hydroxide, patients, 1059 dosage; oral, using clearance rates following i.v. infusion, patients, 66 education; patients, audiovisual, with and without pharmacists present, 63 information; comparison, services, 1215 tablets; sustained-action, comparison, regular aminophylline tablets, effects and blood levels, patients, 613; sustained-action, dosage schedules, blood levels, asthmatic children, 1698
- Thiopental sodium**; incompatibilities; glycopyrrolate, effects, pH, 508
- Thioridazine**; adverse reactions; hyperpyrexia, schizophrenia patient, 674
- Ticarcillin** and amikacin, gentamicin or netilmicin; toxicity, ear, leukopenic patients, 1083 infections; combined therapy, granulocytic cancer patients, 178
- Time studies** admixtures; injections, compounding time and contamination rates, 513 hospital pharmacy; pharmacists, and supportive personnel, comparison, methods, 59 pharmacists; decentralized, emergent, room, costs, 52 pharmacists, hospital; workload, productivity evaluation, 201
- Tobramycin**; drug use review; pharmacists, hospitals, 1209
- Tobramycin sulfate**; incompatibilities; cefoxitin sodium, lack, in vitro, 33
- Tolazoline**; rational therapy; clonidine, overdose, review, 906
- Tolbutamide** adverse reactions; hyponatremia, patients, 1107 tablets; stability, storage, counting machine, spectrometry and colorimetry, 1539
- Toxicity** amikacin and ticarcillin; ear, leukopenic patients, 1083 amphotericin B; review, 1326 ampicillin; diarrhea, prophylaxis, *Lactobacillus acidophilus*, combination, *Lactobacillus bulgaricus*, patients, 754 anticongulants; monitoring, pharmacists, hospital, 214 butorphanol tartrate; side effects, review, 1683 catheters; plastics, thrombosis, effects, physical characteristics, 1707 cephalothin sodium and aminoglycosides; kidney, granulocytic cancer patients, 178 clonidine; overdose, and therapy, review, 906 clofibrate; review, 1326 digitoxin; poisoning, antidotes, patients, 92 digoxin and quinidine sulfate; blood levels, digoxin, increased, patient, 968 drugs; monitoring, computers, programs, hospitalized patients, 198; poisoning, antidotes, effects, electrolyte blood levels, patients, 1366; poisoning, pediatrics, pharmacists, consultation, clinical toxicology service, 1087; skin monitoring, hospitals, patients, 609 estrogens; patients, peri- and postmenopausal, review, 1062 flucytosine; review, 1326 gentamicin and ticarcillin; ear, leukopenic patients, 1083 griseofulvin; review, 1326 injections; i.v., contamination, effects of membrane final-filter pore size on survival, rabbits, 1711; i.v. phlebitis, effects, inline membrane final filters, post-operative patients, 1355 miconazole nitrate; review, 1326 netilmicin and ticarcillin; ear, leukopenic patients, 1083 nitrofurantoin; side effects, review, 342 nystatin; review, 1326 psychotherapeutic agents; extrapyramidal disorders, prophylaxis, antiparkinson agents, patients, 641 quinidine sulfate and digoxin; blood levels, digoxin, increased, patient, 968

ticarcillin and amikacin, gentamicin or netilmicin; ear, in leukemic patients, 1083

#### Tranquillizers

diazepam; tablets, stability, storage, counting machine, spectrometry and colorimetry, 1539

thioridazine; hyperpyrexia, schizophrenic patient, 674

**Trimethoprim:** combination, sulfamethoxazole; effects, mechanism of action, pharmacokinetics, drug interactions and adverse reactions, review, 893; infections, combined therapy, granulocytic cancer patients, 178

**Turnover;** inventory; hospital pharmacy, statistics, 1978

survey, 650

#### U

**Unit dose drug distribution systems,** see Drug distribution systems; unit dose

**Urea;** Reye's syndrome; therapy, review, 767

#### A

**Alexander, Bruce** Book review, 1584

**Alexander, Michael R.** Book review, 1584

**Alexander, Michael R.** Savings achieved through selection of amino acid solutions (letter), 598

**Alexander, Michael R.** see also McGee, Jackie L., 633

**Allen, Loyd V. Jr.** Freezing of suspensions (letter), 1160

**Allen, Loyd V. Jr.** Stability of oral liquid penicillins in unit dose containers at various temperatures, 209

**Allen, Loyd V. Jr.** see also Frech, Gary, 1672

**Allinson, Russel R.** Book review, 1588

**Allinson, Russel R.** Comparison of plastic containers for intravenous solutions (letter), 1035

**Allinson, Russel R.** Compounding times and contamination rates associated with the preparation of intravenous admixtures in three types of plastic containers, 513

**Altman, Michael** see Dasta, Joseph, 613, 1028

**Alvarez, Salvador** see Gleckman, Richard, 342, 893, 1071, 1077, 1509

**Amadio, Peter Jr.** see Vlasses, Peter H., 1046

**Ameer, Barbara** Drug therapy reviews: Evaluation of butorphanol tartrate, 1683

**Amerson, Ann B.** see Magera, Barbara E., 1062

**Anderson, C. W. David** Savings achieved through selection of amino acid solutions (letter), 597

**Anderson, Joan M.** Pharmacy internship: Patient care experience through nursing service, 791

**Anderson, Robert J.** see Spiegel, Robert W., 52

**Archambault, George F.** Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 476

**Armistead, Sidney** Preparation of cardioplegic solutions, 1361

**Arnold, Lawrence A.** Effect of an antacid on gastrointestinal absorption of theophylline, 1059

**Athanikar, Narayan** Visual compatibility of 30 additives with a parenteral nutrient solution, 511

**Autian, John** see Czajka, Peter A., 1087

**Avis, Kenneth E.** Editorial, 1489

**Ayres, James W.** see Ginson, Lee G., 1179

**Ayres, James W.** see also Stennett, Douglass J., 657

#### B

**Bair, Jan N.** Surface characteristics of plastic intravenous catheters, 1707

**Bair, Jan N.** see also Lipman, Arthur G., 1513

**Bair, Jan N.** see also Ruoho, William J., 1355

**Baker, Carol L.** see Knapp, Deanne E., 1334

**Baldwin, Jeffrey N.** see Grogan, Larry J., 205

**Baluch, William** see Ivey, Marianne F., 57, 598

**Barger, Robert** Preparation of sterile, pyrogen-free, bacteriostatic solutions of zinc sulfate and copper sulfate (letter), 1156

**Barreuther, Alan D.** Book review, 1117

**Barriere, Steven L.** Aminoglycoside use monitored by clinical pharmaceutical services, 1209

**Barriere, Steven L.** Book review, 542

**Barriere, Steven L.** Predicting aminoglycoside serum levels (letter), 28

#### V

**Vehicles;** heparin sodium; injections, stability, dextrose in water or sodium chloride, 618

**Vials;** meperidine hydrochloride; dosage forms, adulteration, visual, colorimetry and UV spectrometry, 1094

#### W

**Warfarin;** patient information; hospitals, pharmacists and nurses, 219

**Warfarin sodium** dosage; methodology, prothrombin time, patients, 1351

and heparin sodium; drug use review, pharmacists, hospital, embolism, thrombosis and thrombophlebitis, 214

**Weight** dosage forms; tablets, and capsules, counting machine,

effects on stability, spectrometry and colorimetry, 1539

patients; effects, heparin injection rate, 782

#### Workload

clinical pharmacists; drug use review, hypotensive agents, family-practice clinic, 1665

hospital pharmacy; pharmacists, and supportive personnel, comparison, methods, 59

personnel, pharmacy; supportive, technicians, injections, I.V., comparison, systems, 1497

pharmacists; decentralized, emergency room, costs, 52

pharmacists, hospital; charges, drugs, based upon medication administration records, 365; computers, development of multifunctional drug file, 1197; computers, word-processing machines compared, 1529; outpatients, services, 1978 survey, university-affiliated, 1193; time studies, productivity evaluation, 201

#### X

**Xanthine oxidase inhibitors;** allopurinol; allergies, patients, 1377

## Author Index

**Burkile, Wayne S.** Effect of quinidine on serum digoxin concentrations, 998

**Burkile, Wayne S.** Management of quinidine-induced elevations of serum digoxin (letter), 1480

**Burleson, Ken A.** see Hester, Pat, 1316

**Burleson, Ken W.** see Hester, Pat, 1316

**Busto, Usor** Drug monitoring: The University of Chile Clinical Hospital experience (letter), 596

**Buth, Jonathan A.** Clinical pharmacokinetic articles (letter), 27

#### C

**Cady, William J.** Book review, 109

**Cady, William J.** Use of cholestyramine resin in the treatment of digoxin toxicity, 92

**Campagni, Keith D.** see Sula, Joseph A., 50

**Campbell, James** see Cady, William J., 92

**Carlin, Herbert S.** see Romankiewicz, John A., 1541

**Carlson, Carla** News, 563, 852, 854, 1272

**Chan, Nora L.** Book review, 109

**Chatterji, Dulal C.** see Greene, Raymond F., 38

**Chemella, Frank C.** Continuous versus intermittent intravenous heparin therapy (letter), 1307

**Chemella, Frank C.** Improved method for estimating initial heparin infusion rates, 782

**Childress, K. Jan** see Stallings, Sylvia B., 68

**Cipolle, Robert J.** see Rector, Tom S., 1561

**Cluxton, Robert J. Jr.** Book review, 834

**Cluxton, Robert J. Jr.** Comparison of five information services as sources for bioavailability data, 1215

**Coarse, James F.** Objective-focused approach for appraising the performance of institutional pharmacists, 1676

**Coates, P. E.** see Bartle, W. R., 1701

**Cohen, Edward M.** see O'Brien, Matthew J., 33

**Cohen, Hedy** see Thomas, Russel R., 888

**Cohen, Michael R.** see Thomas, Russel R., 888

**Cohen, Stanley N.** see Tattro, David S., 198

**Cohn, Victor** News, 408

**Collins, G. Edward** see Armistead, Sidney, 1361

**Conner, Christopher S.** Clonidine overdose: A review, 906

**Conner, Christopher S.** Errors in the de Haen Drug-in-Use Drug Information System (letter), 448

**Conte, John E. Jr.** see Barriere, Steven L., 1209

**Conti, Vincent R.** see Armistead, Sidney, 1361

**Cooney, David O.** Sucrose as a sweetener for activated charcoal, 797

**Cross, Martha L.** see McGowan, John E., Jr., 376

**Cullen, Stanley I.** see Stewart, Ronald B., 609

**Cutler, Bruce S.** see Welch, Gary W., 446

**Czajka, Peter A.** Clinical toxicology consultation by pharmacists, 1087

#### D

**Damin, LeeAnne** see Hoffman, Dennis M., 1536

**Darby, Monica H.** see Bryan, Candace Kendle, 1189

**Darr, Marilyn S.** Theophylline education: Development and evaluation of teaching methods, 63

**Dasta, Joseph** Comparison of standard- and sustained-release theophylline tablets in patients with chronic obstructive pulmonary disease, 613

**Dasta, Joseph F.** Emesis in the treatment of paraquat poisoning (letter), 305

Dasta, Joseph F. Estimation of theophylline half-life from theophylline clearance (letter), 1028  
 Deamer, Robert see Athanikar, Narayan, 511  
 Deffenbaugh, Elmer Clarification on legal status of some antihistamine products (letter), 27  
 DeLuca, Alfred R. PPI requirements (letter), 743  
 DeLuca, Patrick P. Binding of drugs to inline filters (letter), 151  
 DeLuca, Patrick P. see also Gatlin, Larry, 1357  
 DeLuca, Patrick see also Rapp, Robert P., 1711  
 DeLuca, Patrick P. see also Rusmin, Simon, 749  
 Demicki, Eugene L. Phenylcyclidine intoxication (letter), 305  
 Derewicz, Henry J. see Hollander, David H., 1163  
 Derewicz, Henry J. see also Roffe, Bruce D., 211  
 Dick, Robert W. see Hanson, Don B., 1197  
 DiGennaro, Stanley B. see Armistead, Sidney, 1361  
 DiPiro, Joseph T. Work sampling to evaluate staff pharmacist productivity, 201  
 Dirks, Isabella Charging for hospital pharmaceutical services: Combined product-service per diem fees, 363  
 Dombrower, Paul Intravenous erythromycin dosages (letter), 1654  
 Domeneq, Catalina see Bustos, Usoa, 596  
 Douglas, Herschel L. see Hawkins, David W., 1321  
 DuBe, James E. see Dar, Marilyn S., 63  
 Duffy, Sister M. Gonzales Realizing the promise of hospital pharmacy, 938  
 Dugas, James E. see Kubica, Anthony J., 194  
 Dwork, Lawrence J. see Thomas, Russell R., 888

**E**

Eckel, Fred M. Book review, 824  
 Edwards, S. Albert Book review, 1114  
 Eichelberger, Bernadette M. News, 122, 258, 563, 992, 1728  
 Ekins, Brent R. Book review, 824  
 Ellenor, Gary L. Book review, 1416  
 El-Mallakh, Hif Incompatibilities with cimetidine hydrochloride injection (letter), 1024  
 Eschbach, Robert C. see Hawkins, David W., 1321  
 Evans, Donna M. Pharmacy practice in an operating room complex, 1342  
 Evans, William E. Book review, 1719  
 Evans, Ronald P. Book review, 1583  
 Evans, Ronald P. Drug therapy reviews: Antirheumatic agents, 622  
 Ewing, Gerald H. see Giaclon, Lee G., 1179

**F**

Fanburg, Barry L. Drug therapy reviews: Treatment of sarcoidosis, 351  
 Faraci, Philip A. see Weiner, Bruce, 444  
 Fezzor, Mike see Ziser, Mark, 1090  
 Feldman, Marvin J. Determining the date of manufacture of drug products from lot numbers, 1545  
 Fielder, Fred P. see Hawkins, David W., 1321  
 Fink, Joseph L. III Patient package inserts and the pharmacist's responsibility, 226  
 Fischer, Robert P. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 473  
 Fish, Kenneth H. Jr. Charging for hospital pharmaceutical services: Computerized system using a markup and a dose fee, 360  
 Fisher, M. M. see Bartle, W. H., 1701  
 Floyd, Ronald A. Book review, 1583  
 Floyd, Ronald A. Estimation of theophylline half-life from theophylline clearance (letter), 1025  
 Floyd, Ronald A. see also Chenella, Frank C., 782  
 Forer, Morris Home drug use by fixed-income patients (letter), 28  
 Fortner, Clarence L. see Bender, John F., 1083  
 Fortner, Clarence L. see also Grove, William R., 452  
 Fotis, Michael see Tribble, Dennis A., 739  
 Fox, Samuel M. Haloperidol in the treatment of phenylcyclidine intoxication (letter), 448  
 Francke, Donald E. Editorial, 455  
 Francke, H. Edward Appreciation expressed for Francke tribute (letter), 1659  
 Francke, Jon E. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 463  
 Francke, Markay M. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 462  
 Fraser, Donald G. Drug therapy reviews: Antimicrobial spectrum, pharmacology and therapeutic use of cefamandole and cefotaxime, 1503  
 Fraterrigo, Carl C. see Palmer, Marcia A., 596, 1025  
 Frazier, Dorothy L. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 470

Frech, Gary Sodium acetate as a preservative in protein hydrolysate solutions, 1672  
 Fredrick, David S. Lidocaine infusions: Effect of duration and method of discontinuation on recurrence of arrhythmias and pharmacokinetic variables, 778  
 Fritz, William L. see Paxinos, James, 1497  
 Frost, John K. see Hollander, David H., 1163  
 Fuentes, Robert J. Formulary decisions concerning cephalosporins (letter), 296  
 Fujitaki, Wayne H. see Tanaka, Gerald J., 1044  
 Fung, Ho-Leung see McNiff, Barbara Lenard, 173

**G**

Gabrielson, R. M. Rational use of methenamine mandelate (letter), 1658  
 Gallelli, Joseph F. see Greene, Raymond F., 38  
 Gallina, Joseph N. see Mahoney, Charles D., 1533  
 Gallo, Ulisse Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 484  
 Garb, Solomon Tobacco addiction among health professionals (letter), 1163  
 Gatlin, Larry Determining osmolarities: A practical approach for multicomponent intravenous and parenteral nutrient solutions, 1357  
 Geiger, Gail S. see Greenlaw, Cal W., 28  
 Gennaro, Alfonso R. see Vlasses, Peter H., 1046  
 Gill, Gary W. see Roffe, Bruce D., 211  
 Gill, Mark A. Altered gentamicin distribution in ascitic patients, 1704  
 Gill, Mark A. Book review, 1588  
 Gill, Mark A. see also Chenella, Frank C., 782  
 Giaclon, Lee G. Pharmacokinetics of orally administered theophylline, 1179  
 Gleckman, Richard Drug therapy reviews: Methenamine mandelate and methenamine hippurate, 1509  
 Gleckman, Richard Drug therapy reviews: Nalidixic acid, 1071  
 Gleckman, Richard Drug therapy reviews: Nitrofurantoin, 342  
 Gleckman, Richard Drug therapy reviews: Oxolinic acid, 1077  
 Gleckman, Richard A. Rational use of methenamine mandelate (letter), 1658  
 Gleckman, Richard Drug therapy reviews: Trimethoprim-sulfamethoxazole, 893  
 Gleckman, Richard see also Rybak, Michael J., 738  
 Godley, Leo F. Honorary members convey gratitude to ASHP (letter), 446  
 Godley, Leo F. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 469  
 Goldstein, Ellie J. C. see Ma, Mary Y., 1055  
 Goldstein, Martin S. Use of the metric system and Celsius scale in U.S. medical and pharmaceutical journals (letter), 1166  
 Good, James W. see Honda, Dennis H., 742  
 Goodhart, Frank W. see Spivey, R. J., 660  
 Gordon, Fred S. see Levine, Howard G., 788  
 Gotz, Vincent Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation, 754  
 Gotz, Vincent P. see also Romankiewicz, John A., 1541  
 Gousse, Gregory C. see DiPiro, Joseph T., 201  
 Gousse, William L. Book review, 838  
 Gouveia, William A. An ASHP SIG on computerized pharmacy systems? (letter), 887  
 Grambau, Geoffrey see Slotfot, Marilyn L., 66  
 Graziani, Leonard J. see Rosenberry, Kathleen R., 736  
 Greenberg, Robert B. The Kennedy version of the Drug Regulation Reform Act, 1230  
 Greene, Raymond F. Stability of cisplatin in aqueous solution, 38  
 Greenlaw, Cal W. Aminoglycoside serum assays restricted through a pharmacy program, 1080  
 Greenlaw, Cal W. Drug interaction between co-trimoxazole and warfarin (letter), 1155  
 Greenlaw, Cal W. Pharmacist as team leader for total parenteral nutrition therapy, 648  
 Greenlaw, Cal W. Standardized heparin dosage schedule using pharmacokinetic principles, 920  
 Greenlaw, Cal W. TPN formulations (letter), 28  
 Greifenhagen, Robert Pharmacy system for screening ambulatory patients, 916  
 Grogan, Larry J. Stability of penicillin V potassium in unit dose oral syringes, 205  
 Grossano, Dennis D. see Hoffman, Dennis M., 1536  
 Groth, Paul E. Modifications in the Paul de Haen Drug Information System (letter), 745  
 Grove, William R. Errors in the de Haen Drugs-in-Use Drug Information System (letter), 452  
 Grove, William R. see also Bender, John F., 1083  
 Grussing, Paul G. see Sula, Joseph A., 50  
 Guenther, Ann M. see Evans, Donna M., 1342  
 Gunter, James M. see Gupta, V. Das, 1094  
 Gupta, Alka see Gupta, V. Das, 1539  
 Gupta, V. Das Simple techniques to detect adulteration of meperidine hydrochloride products, 1094

Gupta, V. Das Stability of some oral solid drug products when stored in a counting machine, 1539

**H**

Haddad, Abraham see Traub, Scott L., 296  
 Haggerity, Jeannette A. Book review, 1114  
 Hagman, Donald see Ingallinera, Thomas S., 508  
 Hahn, Davis M. see Bender, John F., 1083  
 Hak, Lawrence J. Protein requirements in TPN patients (letter), 1036  
 Hales, Kelly Polysaccharide pneumococcal vaccines: A review, 773  
 Haller, Jerome S. Therapy of Reye's syndrome (letter), 1654  
 Hammel, Richard J. see Bootman, J. Lyle, 161  
 Hammel, Richard J. see also Paxinos, James, 1497  
 Hanan, Zachary I. see Levine, Howard G., 788  
 Hanson, Don B. Development of a multi-functional drug file for hospital pharmacy computer applications, 1197  
 Hansten, Philip D. see Jinks, Martin J., 923  
 Harbison, Harry see Athanikar, Narayan, 511  
 Harrison, Willard L. see Klapp, Deborah, 1205  
 Haug, Marcus T. III see Greenlaw, Cal W., 28  
 Haugen, Roger K. see Greenlaw, Cal W., 1080  
 Haughey, David B. Allopurinol sensitivity: Report of two cases, 1377  
 Hawkins, David W. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients, 1321  
 Hays, Dennis P. see Welch, Gary W., 446  
 Helling, Dennis K. Comparison of computer-assisted medical record audit with other drug use review methods, 1665  
 Helling, Dennis K. Effect of direct clinical pharmaceutical services on patients' perceptions of health care quality, 325  
 Helling, Dennis K. see also Brown, David J., 912  
 Henderson, William M. see Arnold, Lawrence A., 1059  
 Henri, Lise Intravenous administration of phenytoin (letter), 295  
 Henrietta, Geoffrey C. see Greenlaw, Cal W., 920  
 Henry, R. Scott see Athanikar, Narayan, 511  
 Hepler, Charles D. see Helling, Dennis K., 325, 1665  
 Herman, Ronald A. see Helling, Dennis K., 1665  
 Herrick, James D. see Miller, Robert F., 371  
 Herstam, Michel Francke Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 462  
 Hester, Pat Comparison of magnesium-aluminum liquid antacids (letter), 1316  
 Hibbard, F. James see Lipman, Arthur G., 1513  
 Hildebrandt, William K. Concomitant use of clonazepam and valproic acid in treatment of epileptic seizures (letter), 22  
 Hirakan, Paul K. see Greene, Raymond F., 38  
 Hirshzman, Joseph L. see Jinks, Martin J., 923  
 Hlynka, John N. Developing drug-use profiles from drug-charge records, 1347  
 Ho, Norman F. H. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 468  
 Ho, Norman F. H. see also Joy, Reuben T., 618  
 Hockensmith, Joel W. see Vlasses, Peter H., 1046  
 Hoffman, Dennis M. Stability of refrigerated and frozen solutions of doxorubicin hydrochloride, 1536  
 Hollandier, David H. Preservative-free heparinized bottle suitable for cytogenetics as well as for cytopathology (letter), 1163  
 Honda, Dennis H. Prepared physician's order form for intravenous cisplatin therapy (letter), 742  
 Hopeff, Alan W. Empiric therapy of febrile granulocytopenic patients, 178  
 Hopkins, Leigh Author affiliation clarified (letter), 1307  
 Hopkins, Leigh E. see also Lee, Mary, 1478  
 Horn, John R. Response rates and direct reprint requests, 1219  
 Hunt, Susan N. Book review, 828  
 Hunter, Robert H. see Cluxton, Robert J., Jr., 1215  
 Hussain, Aswar see Gatlin, Larry, 1357  
 Hutchinson, Richard A. see Meinhold, Jane M., 1520  
 Hutchinson, Richard A. see also Nelson, Arthur A., Jr., 164  
 Hutchinson, Richard A. see also Sula, Joseph A., 50  
 Hyneck, Martha L. see Joy, Reuben T., 618  
 Hyman, Clifford E. Organizational initiatives for hospital pharmacy in the 1980s, 941

Ignoffo, Robert J. Correction of errors in Applied Therapeutics for Clinical Pharmacists (letter), 1044  
 Imhoff, Thomas see Haughey, David D., 1377

- Ingallinera, Thomas S.** Compatibility of glycylcycline injection with commonly used infusion solutions and additives, 508  
**Ivey, Marianne** Administration of hydroxyzine injection (letter), 1660  
**Ivey, Marianne** Savings achieved through selection of amino acid solutions (letter), 598  
**Ivey, Marianne F.** Savings achieved through use of a less concentrated amino acid solution, 57

**J**

- Jacknowitz, Arthur I.** Thioridazine-induced hyperpyrexia—a case report, 674  
**Jakobs, Eleanor** see Scalley, Robert D., 219  
**Jansen, James R.** see Honda, Dennis H., 742  
**Jeffrey, Louis P.** Salary survey of hospital pharmacy residency programs (letter), 1300  
**Jeffrey, Louis P.** see also Mahoney, Charles D., 1533  
**Jensen, Bradford K.** see Grogan, Larry J., 205  
**Jinks, Martin J.** Drug interaction exposures in a Medicaid ambulatory population, 923  
**Johnson, Cary E.** see Slotfeldt, Marilyn L., 66, 453, 745  
**Johnson, Todd A.** see Kellenberger, Thomas A., 230  
**Jones, Mark E.** see Brown, David J., 912  
**Jones, Mark E.** see also Helling, Dennis K., 325  
**Joubert, Dennis W.** see Gleckman, Richard, 342, 893, 1071, 1077, 1509  
**Joy, Reuben T.** Effect of pH on the stability of heparin in 5% dextrose solutions, 618  
**Juhl, Randy P.** Comparison of kaolin-pectin and activated charcoal for inhibition of aspirin absorption, 1097  
**Julison, Dick**, see Mutchie, Kelly D., 785  
**Jump, Walter G.** Estimated versus measured serum digoxin levels (letter), 166  
**Jurgens, Raymond Jr.** see Athanikar, Narayan, 511

**K**

- Kapadia, A. J.** see Ingallinera, Thomas S., 508  
**Katcher, Brian S.** Book review, 1118  
**Katz, Edward** Formulary decisions concerning cephalosporins (letter), 300  
**Katz, Robert E.** see Uliana, Mark, 1024  
**Katz, Robert M.** Society membership and educational program plans for hospital pharmacy supportive personnel (letter), 161  
**Kaul, Alan F.** see Feldman, Marvin J., 1545  
**Kearney, Elizabeth** see Scalley, Robert D., 219  
**Keith, Thomas D.** see Evans, Donna M., 1342  
**Kellenberger, Thomas A.** Essential fatty acid deficiency: A consequence of fat-free total parenteral nutrition, 230  
**Kelly, H. William** Serum theophylline levels in asthmatic children receiving sustained-release theophylline tablets, 1698  
**Kelly, William N.** Book review, 532  
**Kendall, James D.** Determining chronic oral dosage regimens for theophylline (letter), 744  
**Kent, Susan** see Plein, Joy B., 44  
**Kepler, Judith A.** Book review, 1422  
**Kerkhof, Koen** Comparison of plastic containers for intravenous solutions (letter), 1028  
**Kern, Jack W.** see Chenella, Frank C., 782  
**Kern, Jack W.** see also Gill, Mark A., 1704  
**Kessler, Wayne V.** see McBride, Martin H., 1370  
**Keys, Philip W.** Drug interaction between co-trimoxazole and warfarin (letter), 1155  
**Kimberlin, Carole L.** see Darr, Marilyn S., 63  
**King, Charles M. Jr.** Book review, 1247  
**Kirk, Kenneth W.** Book review, 1420  
**Kirschenbaum, Harold L.** Stability of procainamide in 0.9% sodium chloride or dextrose 5% in water (letter), 1464  
**Kirschenbaum, Harold** see Sesin, George P., 1565  
**Kitrenos, Jack G.** Effectiveness of i.v. controllers (letter), 1306  
**Klaesemann, Karen T.** see Hollander, David H., 1163  
**Klap, Deborah** Evaluation of albumin use by medical audit, 1205  
**Klink, Paul R.** Production of carbon dioxide gas after reconstitution of cefamandol nafate (letter), 597  
**Klioze, Oscar** see Ingallinera, Thomas S., 508  
**Kluza, Ronald B.** Book review, 823  
**Knapp, David A.** see Knapp, Deanne E., 1334  
**Knapp, David A.** see also Knapp, Deanne E., 1553  
**Knapp, Deanne E.** Relationship of inappropriate drug prescribing to increased length of hospital stay, 1334  
**Knapp, Deanne E.** see also Knapp, Dee A. (same person)  
**Knapp, Dee A.** Developing criteria for drug prescribing review—A SIG project? (letter), 1465

- Knapp, Dee A.** Strategy for increasing the demand for clinical pharmacists, 1553  
**Knapp, Dee A.** see also Knapp, Deanne E. (same person)  
**Koda, Robert T.** Model for evaluating flow properties of intravenous administration sets, 338  
**Kohlberg, Joshua** Appreciation expressed for Francke tribute (letter), 1659  
**Korberly, Barbara H.** see Rosenberry, Kathleen R., 736  
**Korman, Nancy** see Ignoffo, Robert J., 1044  
**Kotzan, Jeffrey A.** see Segall, L. Elliott, 59  
**Krier, Thomas** Emetics in the treatment of paraquat poisoning (letter), 881  
**Kulkarni, Prakash** see Gatlin, Larry, 1357

**L**

- Lambert, Ivan** see Katz, Robert M., 161  
**Lambert, Ivan** see also Traub, Scott L., 296  
**Lamy, Peter P.** see Grove, William R., 452  
**Lande, Nancy** Book review, 1247  
**Lang, Bela** Appreciation expressed for Francke tribute (letter), 1659  
**Lanning, Laurence J.** Method for evaluating drug information systems, 793  
**Lanse, Steven** see Haughey, David B., 1377  
**Latiolais, Clifton J.** Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 465  
**Latiolais, Clifton J.** see also Allinson, Russell R., 513, 1035  
**Latiolais, Clifton J.** see also Whalen, Forrest J., 330  
**Lau, Steven C.** see Koda, Robert T., 338  
**Lazarus, Herman L.** see Evans, Donna M., 1342  
**Leach, Donald B.** Book review, 1118  
**LeCain, William K.** see Whalen, Forrest J., 330  
**LeClerc, Maurice** Appreciation expressed for Francke tribute (letter), 1660  
**Lee, Herbert** Book review, 1594  
**Lee, Mary** Management of quinidine-induced elevations of serum digoxin (letter), 1478  
**Leonard, Michael S.** see Laning, Laurence J., 793  
**Lesko, Lawrence J.** see Kirschenbaum, Harold L., 1464  
**Letcher, Kenneth I.** Word-processing equipment for hospital pharmacy applications, 1529  
**Levine, Howard G.** Pharmacist involvement in a deferoxamine education program for patients with Cooley's anemia, 788  
**Levinson, R. Saul** see Frech, Gary, 1672  
**Levy, Gerhard** see Slattery, John T., 440  
**Lewis, Benjamin P. Jr.** Potential confusion resulting from trade name similarities (letter), 1477  
**Likes, Keith E.** Book review, 976  
**Lilja, John** Drug product selection by formulary committees in Sweden (letter), 1042  
**Lim, John C.** Technique for microbiological testing of in-use intravenous solutions and administration sets, 1202  
**Lipman, Arthur G.** Decentralization of pharmaceutical services without satellite pharmacies, 1513  
**Lo, Patrick** see Allen, Loyd V. Jr., 209, 1160  
**Lott, Rex S.** Book reviews, 546, 550  
**Louman, F. J. A.** see Bartle, W. R., 1701  
**Love, Lillian J.** see Bender, John F., 1083

**M**

- Ma, Mary Y.** Effect of control programs on cefazolin prescribing in a teaching hospital, 1055  
**MacKay, Mark W.** see Mutchie, Kelly D., 785  
**Magera, Barbara E.** Estrogen therapy of perimenopausal and postmenopausal patients, 1062  
**Mahoney, Charles D.** Pharmacy technician specialist: A career opportunity, 1533  
**Mahoney, Charles D.** see also Jeffrey, Louis P., 1300  
**Majkowski, Kenneth E.** "Mini" in-service education programs for nurses (letter), 1470  
**Makoid, Michael C.** see Grogan, Larry J., 205  
**Mangini, Richard J.** Drug therapy reviews: Pathogenesis and clinical management of hyperuricemia and gout, 497  
**Marsh, Christie**, see Mutchie, Kelly D., 785  
**Mattea, Edward J.** Sterility of prefilled syringes for thermal dilution cardiac output measurements (letter), 1156

- Matthews, Samuel J.** see Gleckman, Richard, 1071, 1077, 1509  
**Matzke, Gary R.** see Burkle, Wayne S., 968, 1490  
**May, Franklin E.** see Stewart, Ronald B., 609  
**Maynard, Susan M.** see Stallings, Sylvia B., 68  
**McBride, Martin H. D.** Deterioration of stannous ion in radiopharmaceutical kits during storage, 1370  
**McDonald, Donald E.** see Tribble, Dennis A., 739  
**McGee, Jackie L.** Phenothiazine analgesia—fact or fantasy?, 633  
**McGehee, William G.** see Chenella, Frank C., 782  
**McGowan, John E. Jr.** Reviewing initial choice of antimicrobial therapy—problems for the individual hospital, 376

- McKeehan, C. Wayne** see Klink, Paul R., 597  
**McKenna, James M.** Effect of advanced pharmaceutical services on the incidence of adverse drug reactions, 1691  
**McLean, J. R.** Radiochemical purity of Tc 99m human serum albumin (letter), 1039

- McManus, Janice** see Romankiewicz, John A., 1541  
**McNiff, Barbara Lenard** Potency and stability of ex-temporaneous nitroglycerin, 173  
**McNiff, Edward F.** see McNiff, Barbara Lenard, 173  
**Meade, Richard H. III** Drug therapy reviews: Antimicrobial spectrum, pharmacology and therapeutic use of erythromycin and its derivatives, 1185  
**Meade, Richard H. III** Drug therapy reviews: Clinical pharmacology and therapeutic use of antimycotic drugs, 1326  
**Meade, Richard H. III** Intravenous erythromycin dosages (letter), 1654

- Meinhold, Jane M.** Audit of anticoagulant therapy of pulmonary embolus, deep vein thrombosis and thromboembolitis, 214  
**Meinhold, Jane M.** Changes in drug information inquiries following implementation of clinical pharmaceutical services, 1520

- Meinhold, Jane M.** see also Nelson, Arthur A. Jr., 164  
**Meltzer, Harvey J.** Charging for hospital pharmaceutical services: Daily professional fee for each drug entity dispensed (letter), 881

- Mendes, Robert W.** see Kirschenbaum, Harold L., 1464

- Mett, Christopher** see Athanikar, Narayan, 511  
**Meyer, Richard D.** see Ma, Mary Y., 1055  
**Milus, Peter** see Cohn, Victor, 408  
**Miller, Donald R.** Predicting warfarin maintenance dosage based on initial response, 1351  
**Miller, Robert F.** Modernizing an ambulatory care pharmacy in a large multi-clinic institution, 371  
**Miller, Russell R.** Book review, 1116  
**Miller, William A.** see Meinhold, Jane M., 214  
**Minor, David R.** see Honda, Dennis H., 742  
**Mirtallo, Jay M.** Book review, 1586  
**Mirtallo, Jay M.** see also Dasta, Joseph, 613, 1028  
**Mitchell, Gary W.** Documenting drug-drug interactions in ambulatory patients, 653

- Moore, Robert C.** Investigational drug information is available to the pharmacist (letter), 1480

- Moore, Terrence N.** see Tatro, David S., 198

- Moore, Timothy D.** Administrative approach to disaster preparedness in the pharmacy, 1337

- Moore, Timothy D.** Developing reimbursable clinical pharmacy programs: Pharmacokinetic dosing service, 1523

- Moore, Timothy D.** Hyponatremia secondary to tolbutamide and chlorothiazide, 1107

- Moore, Timothy D.** see also Kuehnle, Carolyn, 881

- Morris, Marilyn E.** see Parker, William A., 505, 1103

- Moss, Jeffrey** see Gotz, Vincent, 754

- Mueller, William** see Ivey, Marianne F., 57, 598

- Mullens, Patricia Moynahan** see Lanning, Lawrence J., 793

- Murphy, John E.** Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms, 641

- Murphy, John E.** Potential for underdosing of oral liquid medications packaged in unit dose containers (letter), 295

- Murphy, Shirley** see Kelly, H. William, 1698

- Murphy, Henry W.** see Gotz, Vincent, 754

- Mutchie, Kelly D.** Book review, 1588

- Mutchie, Kelly D.** Drug therapy of Reye's syndrome, 767

- Mutchie, Kelly D.** Pharmacist monitoring of parenteral nutrition: Clinical and cost effectiveness, 785

**N**

- Nagai, Noboru** Appreciation expressed for Francke tribute (letter), 1660  
**Nappi, Jean M.** Calculations for dopamine, dobutamine and nitroprusside dosages (letter), 881  
**Naranjo, Claudio A.** see Bustos, Usos, 596  
**Nelson, Arthur A. Jr.** Data analysis in study of physicians' attitudes (letter), 164

- Nelson, Arthur A. Jr. see also Meinhold, Jane M., 1520  
 Newton, David W. Book review, 823  
 Nichols, Ned B. see Mitchell, Gary W., 653  
 Nold, Edward G. Book review, 1594  
 Nold, Edward G. see also Moore, Timothy D., 1523  
 Nold, Edward G. see also Pathak, Dev S., 1527, 1548  
 Nold, Edward G. see also Schad, Randy, 1212  
 Noori, D. S. Differences in professional degrees (letter), 1163  
 Northern, Robert E. Book review, 546  
 Northern, Robert E. see also Brown, Thomas R., 517

**O**

- O'Brien, Matthew J. Cefoxitin sodium compatibility with intravenous infusions and additives, 33  
 Oddis, Joseph A. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 475  
 Oddis, Joseph A. Report of Executive Vice President, 944  
 Ohataki, Takeo Appreciation expressed for Francke tribute (letter), 1660  
 Oke, Tommy Olawuyi Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 478  
 Oliver, Joel A. see Roberts, Raymond W., 1308  
 Oslet, J. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 485  
 Outerian, Glen E. Jr. Incompatibility between carbenicillin injection and promethazine injection (letter), 1156

**P**

- Pakes, Gary E. Phenelzine-cola headache (letter), 736  
 Palmer, Marcia A. Clarification of "explosive-like" reaction occurring when reconstituted cefamandol nafate was stored in syringes (letter), 1025  
 Palmer, Marcia A. Production of carbon dioxide gas after reconstitution of cefamandol nafate (letter), 596  
 Pang, Fred J. see Dirks, Isabella, 363  
 Parker, Paul F. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 469  
 Parker, William A. Incompatibility of diazepam injection in plastic intravenous bags, 505  
 Parker, William A. Oral contraceptive-induced ischemic bowel disease, 1103  
 Paruta, Anthony N. see Mattea, Edward J., 1156  
 Pathak, Dev S. Cost-effectiveness of clinical pharmaceutical services: A follow-up report, 1527  
 Pathak, Dev S. Developing reimbursable clinical pharmacy programs: A goal-oriented approach, 1548  
 Paxinos, James Contamination rates and costs associated with the use of four intermittent intravenous infusion systems, 1497  
 Pearlman, Jeffrey J. see Greifenhagen, Robert, 916  
 Perrin, John H. Freezing of suspensions (letter), 1157  
 Perry, Paul J. Book review, 110  
 Peterson, Charles D. Electrolyte depletion following emergency stomach evacuation, 1366  
 Petersen, Robert V. see Bair, Jan N., 1707  
 Phillips, George L. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 467  
 Pierino, Donna A. see Letcher, Kenneth I., 1529  
 Pierpaoli, Paul G. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 477  
 Pietrusko, Robert G. Drug therapy reviews: Pharmacotherapy of diarrhea, 787  
 Pietrusko, Robert G. Tetracycline and travelers' diarrhea (letter), 1312  
 Placko, John Turkey flavoring for TPN solutions (letter), 1651  
 Platek, Thomas E. Book review, 1420  
 Plein, Elmer M. see Plein, Joy B., 44  
 Plein, Joy B. Drug therapy update for the long-term-care nurse—assessment of need and evaluation of method, 44  
 Portnoff, Joel B. see O'Brien, Matthew J., 33  
 Provost, George P. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 472

**Q**

- Quinn, Suzanne L. see Murphy, John E., 295

**R**

- Raasch, Ralph H. Effects of dextran 70 on factor VIII activity, 89  
 Raeber, Marsha A. see Waller, Elaine S., 806  
 Ramirez-Lassepas, Manuel, see Rector, Tom S., 1561  
 Rapp, Robert P. Sepsin in rabbits following administration of contaminated infusions through filters of various pore sizes, 1711  
 Rapp, Robert P. see also Ruamin, Simon, 749  
 Ray, Max D Editorial, 306  
 Reale, Elaine Obstarczyk see Meinhold, Jane M., 214  
 Rector, Tom S. Characteristics of heparin-associated thrombocytopenia, 1561  
 Reed, Ronald C. see Cluxton, Robert J. Jr., 1215  
 Rehder, Terry L. see Cady, William J., 92  
 Reinders, Thomas P. Pharmacist management of anticoagulant therapy in ambulant patients, 645  
 Reith, Helmut German phenytoin formulation compatible with intravenous fluids (letter), 1317  
 Rhomberg, Mary A. News, 1728  
 Riddiough, Michael A. ASHP, politics and reimbursement (letter), 154  
 Riddiough, Michael A. Ensuring the distribution of PPIs to persons being discharged from hospitals (letter), 1651  
 Rindone, James F. Tetracycline and travelers' diarrhea (letter), 1312  
 Roach, Mark see Cooney, David O., 797  
 Roberts, Raymond W. Alternative to counter-detailing (letter), 1308  
 Rodowikas, Christopher A. Jr. Clinical definitions and training costs (letter), 593  
 Rodowikas, Christopher A. Jr. The Donald E. Francke tribute (letter), 744  
 Roche, Bruce D. Heparinized bottles for the collection of body cavity fluids in cytotechnology, 211  
 Romankiewicz, John A. Medications not to be refrigerated, 1541  
 Romankiewicz, John A. see also Gotz, Vincent, 754  
 Rosenberg, Jack M. Errors in the de Haen Drugs-in-Use Drug Information System (letter), 452  
 Rosenberry, Kathleen R. Combination of clonazepam and sodium valproate in the treatment of refractory epileptic seizures in 12 children (letter), 736  
 Rowland, Clayton see Bootman, J. Lyle, 368  
 Rucker, T. Donald Relative drug safety and efficacy: Any help for the practitioner?, 1999  
 Ruiz, Ines see Bustos, Usoa, 596  
 Rusko, William J. Effect of filtration on complications of postoperative intravenous therapy, 1355  
 Ruamin, Simon Conditions permitting air flow through an air-venting inline filter, 749  
 Russo, John Jr. see Lipman, Arthur G., 1513  
 Rybak, Michael J. Incorrect or unsubstantiated indications listed for selected antimicrobials in the *Physician's Desk Reference* (letter), 736

**S**

- Salter, Fred J. see Ameer, Barbara, 1683  
 Samuelson, Duane see Otterman, Glen E. Jr., 1156  
 Sawyer, William T. see Stallinga, Sylvia B., 68  
 Scalley, Robert D. Interdisciplinary inpatient warfarin education program, 219  
 Schad, Randy F. Hydroxyzine analgesia—fact or fantasy? (letter), 1317  
 Schad, Randy Reimbursable pharmacy teaching program for adrenalectomy patients, 1212  
 Schentag, Jerome J. see Haughey, David B., 1377  
 Schilling, Karl Book review, 1117  
 Schimpff, Stephen C. see Bender, John F., 1083  
 Schneider, Philip J. see Moore, Timothy D., 1523  
 Schneider, Philip J. see also Schad, Randy, 1212  
 Schneeweiss, Fred Interpretation of research idioms (letter), 1303  
 Schumacher, Gerald E. Using pharmacokinetics in drug therapy, IV: Considerations in applying pharmacokinetic and pharmacodynamic estimates to antihypertensive dosage regimens, 802  
 Schumacher, Gerald E. Using pharmacokinetics in drug therapy, V: Contributions to developing dosage regimens for antihypertensive drugs, 1222  
 Schweigert, Bryon F. A letter about Letters (letter), 1651  
 Scott, Evelyn Gray Appreciation expressed for Francke tribute (letter), 1660  
 Scott, Evelyn Gray Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 466  
 Segal, Harold J. Book review, 1421  
 Segall, L. Elliott Comparison of two methods of observing work areas in a hospital pharmacy, 59  
 Seifert, Randall D. see Rector, Tom S., 1561  
 Sesin, G. Paul see Kirschenbaum, Harold L., 1464  
 Sesin, G. Paul see also Sesin, George P. (same person)

- Sesin, George P. Folic acid hypersensitivity and fever: A case report, 1565

- Sesin, George P. see also Sesin, G. Paul (same person)  
 Sewell, Winifred Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 481  
 Shaw, Stanley M. see McBride, Martin H. D., 1370  
 Shearer, Cameron A. see Parker, William A., 505, 1103  
 Shelver, William H. see Arnold, Lawrence A., 1059  
 Sherrin, Thomas P. see Allinson, Russell R., 513, 1035  
 Shulman, Jonas A. see McGowan, John E. Jr., 376  
 Silberg, Ronald see Anderson, C. W. David, 597  
 Simonmeyer, Larry M. Pharmacy inspections: Constitutional without a warrant?, 85  
 Simonson, William Estimated versus measured serum digoxin levels (letter), 166  
 Simonson, William see also Stennett, Douglass J., 657  
 Simpson, Thomas R. see Schweigert, Byron F., 1651  
 Silverman, Harold M. ASHP membership dues (letter), 1307  
 Skolaut, Milton W. Report of Treasurer, 946  
 Skolaut, Milton W. see also Ziser, Mark, 1090  
 Skoutakis, Vasilios A. see Czajka, Peter A., 1087  
 Slattery, John T. Pharmacokinetic model of acetaminophen elimination (letter), 440  
 Slotfeldt, Marilyn L. Determining chronic oral dosage regimens for theophylline (letter), 745  
 Slotfeldt, Marilyn Dose-dependent versus first-order kinetics in theophylline elimination (letter), 453  
 Slotfeldt, Marilyn L. Reliability of theophylline clearance in determining chronic oral dosage regimens, 66  
 Smith, Dorothy L. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 479  
 Smith, Gary H. Book review, 1417  
 Smith, Joe E. see Anderson, Joan M., 791  
 Smith, Kristie A. see Mutchie, Kelly D., 785  
 Smith, William E. Charging for hospital pharmaceutical services: Product cost, per diem fees and fees for special clinical services, 355  
 Smith, William E. Jr. see Hlynka, John N., 1347  
 Sonnedecker, Glenn Remarks at the memorial service (tribute to Donald E. Francke), 459  
 Sorkness, Ronald Therapeutic problem solving: A systematic approach, 798  
 Souney, Paul F. see Feldman, Marvin J., 1545  
 Sparkman, Helen E. Experience with cimetidine oral suspension formulation (letter), 600  
 Speedie, Marilyn K. see Knapp, Deanne E., 1334  
 Spiegel, Robert W. Comprehensive pharmaceutical services in the emergency room, 52  
 Spivey, R. J. In vitro acid reactivity of three commercial antacid tablets, 660  
 Spurbeck, George H. see Arnold, Lawrence A., 1059  
 Stach, Paul E. Book review, 1253  
 Stach, Paul E. see also Allinson, Russell R., 513, 1035  
 Stallings, Sylvia B. Comparison of natriuretic and diuretic effects of single and divided doses of furosemide, 68  
 Stanaszek, Walter F. see Mitchell, Gary W., 653  
 Stein, Z. L. G. Diagnosis of sarcoidosis (letter), 744  
 Stein, Z. L. G. Pokeweed-induced gastroenteritis (letter), 1303  
 Stein, Z. L. G. Quinidine-digoxin interaction (letter), 1307  
 Steiner, Gilbert A. Book reviews, 386, 702  
 Steinke, William E. see Reinders, Thomas P., 645  
 Stennett, Douglass J. Effect of membrane filtration on 10-mg/ml cefazolin admixtures, 657  
 Stennett, Douglass J. see also Simonson, William, 166  
 Stewart, Kenneth R. see Gupta, V. Das, 1094  
 Stewart, Ronald B. Book review, 1421  
 Stewart, Ronald B. Dermatologic adverse drug reactions in hospitalized patients, 609  
 Stewart, Ronald B. see also Murphy, John E., 641  
 Stewart, Ronald B. see also Yost, Richard L., 1372  
 Stiles, M. Lou see Frech, Gary, 1672  
 Stolt, Richard P. see Wallner, Jon N., 1193  
 Stolar, Michael H. Assuring the quality of intravenous admixture programs, 605  
 Stolar, Michael H. Editorials, 170, 1053  
 Stolar, Michael H. Hospital pharmacy purchases and inventories, 650  
 Stolar, Michael H. National survey of hospital pharmaceutical services—1978, 316  
 Stolley, Stephen N. see Greenlaw, Cal W., 920  
 Sturgeon, Roy see Athanikar, Narayan, 511  
 Sula, Joseph A. Structured educational program for staff development, 50  
 Summerfield, Marc Warning label for intravenous use of vesicants (letter), 1470  
 Summerfield, Marc R. Book review, 828  
 Superstein, Edward Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 476  
 Swanson, Larry N. Book review, 1579  
 Swartz, Allan J. Staff evaluation, 187  
 Swerling, Richard Importance of maintaining and

promoting prescription compounding skills (letter), 1477

## T

- Tallett, Eric R. Assuring the quality of intravenous admixture programs (letter), 1317  
 Tally, C. Richard News, 410, 1128  
 Tanaka, Gerald J. Pharmacist-prepared drug therapy reviews for family practice medical residents (letter), 1044  
 Tatro, David S. Book review, 391  
 Tatro, David S. Computer-based system for adverse drug reaction detection and prevention, 198  
 Teasley, Kathy M. see Hak, Lawrence J., 1036  
 Tempio, Joseph S. Extemporaneous preparation of cimetidine oral suspension (letter), 1039  
 Tharaldson, Thomas see Krier, Thomas, 305  
 Thomas, Russell R. Counter-detailing of drugs by pharmacists (letter), 888  
 Tobin, Morris see Haughey, David B., 1377  
 Tomasulo, William J. see Levine, Howard G., 788  
 Tortorici, Michael P. Formulation of a cimetidine oral suspension (letter), 22  
 Traub, Scott I. Definition of clinical pharmacy (letter), 296  
 Treadwell, Barbara E. Thiopental sodium and pentobarbital sodium in the treatment of Reye's syndrome (letter), 1480  
 Trestrail, John H. III Book reviews, 823, 1417  
 Tribble, Dennis A. Unit-of-use versus traditional intravenous piggyback drug administration systems (letter), 739  
 Troutman, William G. see Weber, Stanley S., 1567  
 Trujeque, Laurence see Weber, Stanley S., 1567  
 Tuttle, C. Brian Book review, 1721

## U

- Uliana, Mark Allergy labels for unit dose medication drawers (letter), 1024  
 U.S. General Accounting Office GAO report on hospital purchasing and inventory management, 1171

## A

- Abbott Laboratories  
 H-BIG, 291, 547  
 IVEX-2, 102-103, 239, 392-393, 426, 672-673, 720  
 Panheprin, 873-874, 1029-1030, 1273-1274, 1433-1434, 1723-1724  
 Adria Laboratories, Inc.  
 Adrucil, 16-17, 262-263, 382-383, 530-531, 586-587, 858-859, 1244-1245, 1296-1297  
 AFS International/Intercultural Programs  
 Institutional, 824  
 American Lung Association  
 Christmas Seal, 1732  
 American Pharmaceutical Association  
 APHA Drug Names, 815  
 American Pharmacy Corporation  
 Positions Available, 94, 234, 286  
 American Society for Parenteral and Enteral Nutrition, Inc.  
 4th Clinical Congress, 1416  
 American Society of Hospital Pharmacists  
 American Hospital Formulary Service, 1022, 1226  
 Handbook of Drug Therapy, 1251  
 Handbook of Institutional Pharmacy Practice, 1257  
 Handbook on Injectable Drugs, 568, 1664  
 International Pharmaceutical Abstracts, 434  
 Manual for Hospital Pharmacy Technicians, 1150  
 Medication Teaching Manual, 928  
 Patient Education Programs, 860  
 Sourcebook on Computers in Pharmacy, 927  
 Sourcebook on Unit Dose Drug Distribution Systems, 1110, 1146  
 Wiley's Professional Development Programs, 432  
 Ames Color-File, Division of Ames Safety Envelope Company  
 Kompress Mobile Shelving, 1281  
 Arnar-Stone Laboratories, Division of American Hospital Supply Corporation  
 Bretylol and Intropin, 532-536, 688-692, 828-832  
 Intropin, 244-246, 282-284, 882-883, 1270-1271  
 Position Available, 1613

## V

- Valette, Guillaume Appreciation expressed for Francke tribute (letter), 1660  
 Vander Salm, Thomas J. see Welch, Gary W., 446  
 Van Leuven, Marcel see Athanikar, Narayan, 511  
 Varano, Carmine The Donald E. Francke tribute (letter), 743  
 Visconti, James A. see Rucker, T. Donald, 1099  
 Vitale, Paul J. see Summerfield, Marc, 1470  
 Vlasses, Peter H. Urine test as a potential aid in testing for patient compliance with methyldopa therapy (letter), 1046

## W

- Wagner, Frederick H. see Roffe, Bruce D., 211  
 Wagner, James R. see Hanson, Don B., 1197  
 Walker, H. Kenneth see McGowan, John E. Jr., 376  
 Wallace, David L. see Plein, Joy B., 44  
 Waller, Elaine S. Relapsing polychondritis in a Latin American man, 806  
 Wallner, Jon N. Survey of outpatient pharmaceutical services in university hospitals, 1193  
 Wasserman, Albert J. see McKenney, James M., 1691  
 Watanabe, Arthur S. see Conner, Christopher S., 906  
 Watson, Bill Absence status and the concurrent administration of clonazepam and valproate sodium (letter), 887  
 Weber, Robert E. Readability of PPIs (letter), 305  
 Weber, Stanley S. Effect of hemodialysis on plasma naproxen concentration, 1567  
 Weg, John G. see Slotfeldt, Marilyn L., 66  
 Weiblein, Jack W. see Smith, William E., 355  
 Weinberger, Miles Dose-dependent versus first-order kinetics in theophylline elimination (letter), 452  
 Weiner, Bruce Salt substitute as a potassium supplement (letter), 444  
 Welch, Gary W. Hemolysis caused by mislabeled saline solution (letter), 446  
 Welco, Alan see Athanikar, Narayan, 511  
 Welsh, W. J. see McLean, J. R., 1039  
 Wertheimer, Albert I. Book review, 1588  
 Wertheimer, Albert I. see also Bootman, J. Lyle, 368  
 Whalen, Forrest J. Availability of insulin from continuous low-dose insulin infusions, 330  
 White, Eugene V. Remembrances: Family, friends, stu-

- dents and colleagues (tribute to Donald E. Francke), 446  
 Whiten, Ron E. Comparison of magnesium-aluminum liquid antacids (letter), 1316

- Whiten, Ron E. Formulary selection of magnesium and aluminum combination liquid antacids (letter), 739

- Whittet, T. Douglas The transition from apothecary to pharmacist in British hospitals, 492

- Wiernik, Peter H. see Bender, John F., 1083

- Williams, Frank F. see Thomas, Russell R., 888

- Williams, Paul J. see Hak, Lawrence J., 1036

- Wilson, Andrew L. see Schumacher, Gerald E., 802

- Wilson, Emery see Magera, Barbara E., 1062

- Winters, J. H. M. Remembrances: Family, friends, students and colleagues (tribute to Donald E. Francke), 482

- Wissinger, Robert A. see Gouveia, William A., 887

- Wolfe, Lawrence W. see Thomas, Russell R., 888

- Wood, George C. see Czajka, Peter A., 1087

- Wood, Warren A. TPN formulations (letter), 29

- Woodcock, Thomas M. see Hoffman, Dennis M., 1536

- Worthen, Leonard R. see Mattea, Edward J., 1156

- Wyatt, Benji K. Charging for hospital pharmaceutical services: Flat fee based on the medication record, 365

## Y

- Yaeger, Donna M. see Knapp, Deanne E., 1334  
 Yost, Richard L. ASHP Midyear Clinical Meeting papers: 1967-1978, 1372

- Young, W. Wayne see Darr, Marilyn S., 63

## Z

- Zalai, K. Appreciation expressed for Francke tribute (letter), 1660  
 Zaske, Darwin E. see Bootman, J. Lyle, 368  
 Zaske, Darwin E. see also Kellenberger, Thomas A., 230  
 Zellmer, William A. Editorials, 31, 169, 307, 603, 747, 891, 1169, 1319, 1490, 1663  
 Ziser, Mark Regulating intravenous fluid flow: Controller versus clamps, 1090

## Advertising Index

Ascot Hospital Pharmaceuticals, Inc.  
 Hydroxyzine, 1587

Automated Prescription Systems, Inc.  
 Baker AutoScript, 1409

## B-C

Becton-Dickinson, Division of Becton, Dickinson and Company  
 Glaspak Syringe, 99, 1455

Beecham Laboratories  
 Ticar, 730-732, 1130-1132, 1298-1300, 1628-1630

Breon Laboratories, Inc.

Bronkosol, 1460-1461, 1620-1621

Bristol Laboratories, Division of Bristol-Myers Company

Amikin, 23-26, 235-238, 273-276

Cefadyl, 156-158, 388-390, 428-430, 818-820, 884-886,

1032-1034, 1254-1256

Kantrex, 100-101, 164-165, 296-297, 584-585, 834-835,

986-987, 1235-1226, 1383-1384

Maxete, 1482-1484, 1637-1639

Stadol, 3-6, 265-268, 287-290, 435-438

Burron Medical Products, Inc.

Filter Needle II, 967

Filtration Systems, 556-557, 700-701, 1436-1437

Secondary I.V. Set, 1320

Burroughs Wellcome Company

Empirin # Codeine, 1582, Dec-IFC

Lanoxin, 125-126, 411-412, 679-680, 973-974, 1381-

1382, 1655-1656

Canadian Pharmaceutical Association

Position Available, 966

Cedars of Lebanon Health Care Center

Positions Available, 678

Connaught Laboratories, Inc.

Albucon and Tel-Conn-G, Jan-OBC, Feb-OBC, 380,

687, Aug-OBC, 1429

## D-F

Drug Intelligence Publications, Inc.

Handbook of Clinical Drug Data, 524

Problems in Pediatric Drug Therapy, 1729

Elkins-Sinn, Inc., Subsidiary of A. H. Robins Company

Hep-Lock, 104, 138, Mar-OBC, Apr-OBC,

Lidocaine, 703, Jun-OBC, Jul-OBC, 1027, Sep-OBC,

Oct-OBC, 1452, Dec-OBC

Elsevier North Holland Inc.

Drugs Therapeutics, 805

Pharmacy International, 1578

Emblem-Medic Industries

Unit Dose Packaging, 117, 413, 857

Facts and Comparisons

Publication, 1115, 1246, 1414

## Index

**Flint Laboratories, Division of Travenol Laboratories, Inc.**  
Synthroid, 542-543, 708-709  
**E. Fougera & Co. Division of Byk-Gulden, Inc.**  
Efodine, 439, 1051, 1240  
Foilpac, 592  
Institutional, 1-90  
Surgilube, 717  
**Fresno Community Hospital and Medical Center**  
Position Available, 1569

## G-I

**Geigy Pharmaceuticals, Division of Ciba-Geigy Corporation**  
Lopressor, Jan-IFC, Feb-IFC, Mar-IFC, Apr-IFC, May-IFC, Jun-IFC, Aug-IFC, Sep-IFC, Oct-IFC, Nov-IFC  
**Gen Refrigerator**  
Refrigerator, 88, 261, 386, 558, 600, 822, 979, 1123, 1258, 1405, 1554, 1657  
**Hamilton Industries**  
Laboratory Equipment, 559, 1157  
**HPI Hospital Pharmacies**  
Institutional, 1458  
Positions Available, 1726  
**Hoechst-Roussel Pharmaceuticals, Inc.**  
Lasix, 421, 671  
**IMED Corporation**  
Volumetric Infusion Pumps, 667, 1318  
**International Pharmaceutical Federation**  
Membership, 1733  
**Invenex Laboratories**  
Magnesium Sulfate Injection, 129-130  
Lidocaine, 159-160  
**IVAC Corporation**  
IVAC 230 Controller, 8-9, 134-135, 302-303, 988-989, 1142-1143, 1388-1389, 1486-1487  
IVAC 630 Pump, 551-554, 576-577, 734-735

## J-L

**Jewett Refrigerator Company, Inc.**  
Refrigerators, 1026, 1397, 1625  
**Johnson & Johnson**  
Pancrease, 136-137, 450-451, 740-741, 1008-1009  
**Keweenaw Scientific Equipment Corporation**  
Institutional, 1241, 1401, 1584  
**Knoll Pharmaceutical Company**  
Dilaudid, 155, 449, 1047, 1479  
**Lansing General Hospital**  
Position Available, 1569  
**Lea & Febiger**  
Publications, 699  
**Lenox Hill Hospital**  
Position Available, 1569  
**Lifemark Corporation**  
Grant Awards Program, 1589  
Positions Available, 1731  
**Eli Lilly and Company**  
Institutional, 106-107, 142-143, 298-299, 544-545, 578-579, 840-841, 876-877, 1126-1127, 1140-1141, 1386-1387, 1456-1457, 1642-1643  
Kefzol, 447-448, 693-694, 727-728, 997-998, 1045-1046, 1149-1150, 1287, 1605

## M

**MacBick, Division of C. R. Bard, Inc.**  
Medication Carts, 1263, 1617  
**Market Forge**  
Medication Carts, Apr-IBC  
Medication Handling Equipment, 7, 1449, 1627  
**McGraw Laboratories, Division of American Hospital Supply Corporation**  
Accumed, 1040-1042, 1304-1306, 1574-1575, 1644-1646  
Institutional, 1471-1476, 1631-1636  
**Mead Johnson Pharmaceutical Division, Mead Johnson and Company**  
Mucomyst, 1596-1598, 1648-1650  
Unit Dose, 108, 240, 304  
**Medi-Dose, Inc.**  
Medi-dose/Medi-cup System, 19, 250, 453, 725, 1025, 1417

**Herman Miller, Inc.**  
The Co/Struc System, 133, 387, 445, 1003, 1167, 1595  
**Millipore Corporation**  
Addi-Chek, 10, 278, 580, 1052, 1259  
Milllex, 1411, 1413, 1415, 1579, 1581, 1583  
**Modern IV Practices**  
MIVP Program, 1248-1249, 1418-1419  
**Modern Metals Industries, Inc.**  
Unit Dose Systems, 1028, 1407

## N-P

**National Society for the Prevention of Blindness**  
Institutional, 856  
**Ochsner Foundation Hospital**  
Position Available, 1727  
**The Ohio State University Hospitals**  
Pharmacy Technician Training Manual, 928  
**Omnimed, Inc.**  
Locks and Links, 597  
Perineze, 1589  
**Organon Pharmaceuticals, Division of Organon Inc.**  
Deca-Durabolin, 95, 171, 277, 562, 682  
Hexadrol, 121, 251, 417, 458, 713, 801, 1102, 1229, 1441, 1560  
**The Owen Company**  
Positions Available, 846, 1124, 1269, 1422, 1478, 1727  
**Parke, Davis and Company, Division of Warner-Lambert Company**  
Documed, 1054, 1170, 1492  
Nitrostat, 71, 109, 286, 391, 666, 686, 927, 975, 1247, 1278  
Uni/Use, 866-867, 1120-1121, 1238-1239, 1292-1293, 1610-1611  
**Pharmaceutical Associates**  
Generic Liquid Pharmaceuticals, 1491  
**Pharmaseal Laboratories, Division of American Hospital Supply Corporation**  
Pharm-Aide, 1110, 1430, 1481  
**Philadelphia College of Pharmacy and Science**  
Pharmacy Management, 12, 529  
**Philips Roxane Laboratories, Inc., a Boehringer Ingelheim, Ltd. Company**  
Liquid Unit Dose, 1004-1005, 1264-1265, 1424-1425, 1488-1489  
Lithium Citrate, 21, 257, 379, 433, 681  
Milk of Magnesia, 30, 168, 306, 454, 602, 746, 890  
**Production Equipment, Inc.**  
Counters, 151, 565, 743, 1113, 1392, 1659  
**PSG Publishing Company**  
Clinical Pharmacy Sourcebook, 1116  
**The Purdue Frederick Company**  
Betadine, 32, 385, 707, 889, 1275, 1439

## R-T

**Red Cross**  
CPR Training, 856  
**Reynolds and Reynolds**  
Unit Dose System, 1459, 1715  
**Roche Laboratories, Division of Hoffmann-La Roche Corporation**  
Institutional, 118-119, 254-255, 404-405, 526-528, 683-685, 825-827, 1279-1280, 1375-1376, 1571-1572  
**Roche Products, Inc.**  
Dalmane, 97-98, 399-400, 573-574, 1161-1162, 1601-1602, 1640-1641  
**Sandoz Pharmaceuticals**  
Institutional, 457, 1031, 1647  
Sando-Pak, 167, 839, 1385  
**Searle Laboratories, Division of Searle Pharmaceuticals, Inc.**  
Institutional, 285, 537, 575, 833  
**Sigmanotor, Inc.**  
Sigma 5000, 591, 999  
**Smith Kline & French Laboratories, Division of SmithKline Corporation**  
Acef, 111, 259, 401, 523, 705, 851, 990-992, 1014-1016, 1158-1160  
Comazine, 144-145, 548-549, 718-719, 1006-1007, 1242-1243, 1294-1295, 1618-1619  
Institutional, 248-249, 422-423, 696-697, 842-843, 1466-1467  
Tagamet, 1450-1451, 1652-1653  
**Stony Brook University Hospital**  
Positions Available, 971  
**St. John's University**  
Positions Available, 170

**Stuart Pharmaceuticals, Division of ICI Americas, Inc.**  
Effersyllium, 127, 260, 407, 521, 695, 748, 1557-1558, 1717-1718  
**SystaModules, Division of General Equipment Corporation**  
Institutional, 84, 172, 415, 567, 604, 816, 892, 1111, 1252, 1412, 1580, 1662  
**Teach'em, Inc.**  
Voices, 83, 855, 1720  
**Travenol Laboratories, Inc.**  
Filters, 879-880, 1037-1038, 1267-1268, 1301-1302, 1557-1558, 1717-1718  
Mini-Bag, 112, 865  
Travasol, 147-150, 981-984  
Vinflex, 269-270, Jun-IBC, Jul-IBC, Aug-IBC, 1168, Oct-IBC, 1488, Dec-IBC

## U

**UCLA**  
Positions Available, 710  
**United Hospital Supply Corporation**  
Unit Dose Medication Systems, 875, 1035  
**United States Pharmacopeial Convention**  
Publication, 1585  
**The United Way**  
Institutional, 928  
**University of Alberta**  
Positions Available, 406  
**University of Arizona**  
Positions Available, 406, 678, 1625  
**University of Arkansas**  
Position Available, 560  
**University of Colorado**  
Positions Available, 229, 403, 416, 980, 1722  
**University of Iowa**  
Clinical Pharmacy Fellowship, 561  
**University of Michigan Hospitals**  
Positions Available, 1266, 1431, 1590  
**University of Minnesota**  
Position Available, 1722  
**University of Pennsylvania**  
Symposium, 566  
**University of Southern California**  
Position Available, 1380, 1554  
**University of Tennessee Center for the Health Sciences**  
Training Programs, 704  
**University of Texas System Cancer Center**  
Oncology Symposium, 1250  
**University of Wisconsin**  
Position Available, 1431  
**The Upjohn Company**  
Cleocin, 14-15, 394-395, 594-595  
Institutional, 848-849  
Motrin, 1309-1312, 1591-1594  
**Upsher-Smith Laboratories, Inc.**  
Acetaminophen, Sep-IBC, Nov-IBC  
Klor Con "G", Jan-IBC, Feb-IBC, Mar-IBC, May-IBC  
**USV Laboratories, Division of USV Pharmaceutical Corporation**  
M.V.I., 598-599, 852-853, 1276-1277, 1442-1443, 1576-1577

## W-Y

**Warner-Chilcott, Division of Warner-Lambert Company**  
Dispos-a-Vial, 162-163, 424-425, 844-845  
**Waterloo Industries**  
Med-Cart, 384, 525, 861, 1021, 1253, 1421, 1603  
**Wayne State University**  
Position Available, 990  
**Wheaton Scientific**  
I.V. Additive Pump Chamber Assembly, 243, 1573  
Uni-Dose, 241, 817, 1117, 1719  
Unispense, 242, 823, 1148  
Zippettes, 105, 1721  
**Winthrop Laboratories**  
Carpject, 247, 301, 541, 601, 737, Jul-IFC, 1043, 1144  
**Wyeth Laboratories**  
Heparin, 81-82, 309-310, 711-712, 977-978, 1227-1228, 1555-1556  
**Yale-New Haven Hospital**  
Position Available, 1316, 1727

